<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN" "https://jats.nlm.nih.gov/publishing/1.1/JATS-journalpublishing1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" specific-use="sps-1.9" dtd-version="1.1" xml:lang="pt" article-type="case-report">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">abc</journal-id>
      <journal-title-group>
        <journal-title>Arquivos Brasileiros de Cardiologia</journal-title>
        <abbrev-journal-title abbrev-type="publisher">Arq. Bras. Cardiol.</abbrev-journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0066-782X</issn>
      <issn pub-type="epub">1678-4170</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Cardiologia - SBC</publisher-name>
        <publisher-loc>S&#227;o Paulo, SP, Brazil</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v3">kMKCryzH3wLZsmcQ8Xg5CXr</article-id>
      <article-id pub-id-type="other">00023</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v2">S0066-782X2010000200023</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v1">S0066-782X(10)09400223</article-id>
      <article-id pub-id-type="doi">10.1590/S0066-782X2010000200023</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Relato de Caso</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Caso 1 - Homem de 59 anos com obesidade acentuada, hipertens&#227;o arterial, insufici&#234;ncia card&#237;aca e submetido a anticoagula&#231;&#227;o para fibrila&#231;&#227;o atrial, apresentou acidente vascular cerebral e septicemia</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Veronese</surname>
            <given-names>Pedro</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Benvenuti</surname>
            <given-names>Luiz Alberto</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
      </contrib-group>
      <aff id="aff01">
        <addr-line>
          <named-content content-type="city">S&#227;o Paulo</named-content>
          <named-content content-type="state">S&#227;o Paulo</named-content>
        </addr-line>
        <institution content-type="orgname">Universidade de S&#227;o Paulo</institution>
        <institution content-type="orgdiv1">FM </institution>
        <institution content-type="orgdiv2">HC</institution>
        <country country="BR">Brazil</country>
      </aff>
      <pub-date date-type="collection" publication-format="electronic">
        <month>02</month>
        <year>2010</year>
      </pub-date>
      <volume>94</volume>
      <issue>2</issue>
      <fpage>282</fpage>
      <lpage>288</lpage>
      <permissions>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/" xml:lang="en">
          <license-p>This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.</license-p>
        </license>
      </permissions>
      <pub-date publication-format="electronic" date-type="pub">
        <day>05</day>
        <month>05</month>
        <year>2010</year>
      </pub-date>
    </article-meta>
  </front>
  <body>
    <p>
      <bold>CORRELA&#199;&#195;O ANATOMO-CL&#205;NICA</bold>
    </p>
    <p>
      <bold>Caso 1 - Homem de 59 anos com obesidade acentuada, hipertens&#227;o arterial, insufici&#234;ncia card&#237;aca e submetido a anticoagula&#231;&#227;o para fibrila&#231;&#227;o atrial, apresentou acidente vascular cerebral e septicemia</bold>
    </p>
    <p>
      <bold>Pedro Veronese; Luiz Alberto Benvenuti</bold>
    </p>
    <p>Instituto do Cora&#231;&#227;o (InCor) HC-FMUSP, S&#227;o Paulo</p>
    <p>
      <xref ref-type="corresp" rid="back">Correspond&#234;ncia</xref>
    </p>
    <p><bold>Palavras-chave: </bold> Obesidade,hipertens&#227;o, insifici&#234;ncia card&#237;aca, acidente vascular cerebral, sepse.</p>
    <p>Homem obeso de 59 anos de idade foi internado com hemiplegia esquerda.</p>
    <p>O paciente foi atendido pela primeira vez no Hospital aos 54 anos de idade, em raz&#227;o de crise de dispneia intensa e hipertens&#227;o arterial.</p>
    <p>Recebeu o diagn&#243;stico de hipertens&#227;o arterial aos 44 anos de idade, quando apresentou quadro de dispneia intensa e hipertens&#227;o arterial com n&#237;veis tensionais de 220/120 mmHg. Procurou atendimento m&#233;dico de emerg&#234;ncia e foi medicado. Evoluiu com dispneia acompanhada de sudorese profusa e aperto retroesternal desencadeados por esfor&#231;os moderados. Fez tratamento irregular. Na evolu&#231;&#227;o apresentou epis&#243;dios de ronco intenso durante o sono com sensa&#231;&#227;o de sufocamento ao despertar. O paciente sabia ser obeso desde a juventude, contudo houve maior ganho de peso desde a idade de 48 anos.</p>
    <p>O exame f&#237;sico (12 mar 2001) revelou peso 163,8 kg, altura 1,74 m, &#237;ndice de massa corp&#243;rea de 54,1 kg/m<sup>2</sup>, pulso de 84 bpm, press&#227;o arterial 200/110 mmHg. A semiologia pulmonar foi normal. O choque da ponta do cora&#231;&#227;o foi palpado no 6<sup>&#186;</sup> espa&#231;o intercostal, para fora da linha hemiclavicular esquerda, e a ausculta n&#227;o revelou bulhas acess&#243;rias. Havia sopro sist&#243;lico ++/4+ em &#225;rea mitral e borda esternal esquerda. O abdome era volumoso, em avental, sem visceromegalias. Havia edema discreto de membros inferiores e os pulsos nesses membros estavam diminu&#237;dos.</p>
    <p>A radiografia de t&#243;rax (7 mar 2001) revelou cardiomegalia +++/4+ com aumento global do cora&#231;&#227;o;</p>
    <p>O eletrocardiograma (7 mar 2001) revelou ritmo sinusal, frequ&#234;ncia card&#237;aca 77 bpm, intervalo PR 172 ms, dura&#231;&#227;o de QRS 96 ms, intervalo QT 372 ms, o eixo de QRS a -30<sup>0</sup> para tr&#225;s, havia entalhe inicial com onda QS III e aVF, onda R n&#227;o progressiva de V1 a V3 e perda de potenciais em deriva&#231;&#245;es esquerdas (<xref ref-type="fig" rid="f01">Figura1</xref>).</p>
    <p content-type="asset">
      <fig id="f01">
        <graphic xlink:href="1678-4170-abc-94-02-0282-00023-gf01.jpg"/></fig>
    </p>
    <p>Os exames laboratoriais (8 mar 2001) revelaram 14,4 g/dl de hemoglobina, hemat&#243;crito 43%, &#225;cido &#250;rico 9 mg/dl, creatinina 1,6 mg/dl, pot&#225;ssio 4,4 mEq/l, s&#243;dio 145 mEq/l, glicemia de jejum 148 mg/dl, colesterol total 121 mg/dl, triglic&#233;rides 57 mg/dl; o exame de urina revelou protein&#250;ria de 0,25 g/l, sem outras altera&#231;&#245;es. O n&#237;vel de TSH foi 5,28 U/ml, T4 livre 1,1 ng/dl, leptina 31 ng/ml (normal 3,8&#177;1,8 ng/ml), testosterona 336 ng/ml, FSH 2,6 UI/l, LH 2,0 UI/l, estradiol 40,2 pg/ml, insulina 7,9 Ul/ml, cortisol urin&#225;rio 261 g/24 h e sulfato de hidroepiandrostenediona 1.457 ng/ml.</p>
    <p>O ecocardiograma (26 abr 2001) revelou espessura de septo e de parede posterior de 10 mm, di&#226;metro de aorta de 32 mm, de &#225;trio esquerdo de 52 mm, di&#226;metro diast&#243;lico de ventr&#237;culo esquerdo de 70 mm e o sist&#243;lico 57 mm, com fra&#231;&#227;o de eje&#231;&#227;o de 46%, por hipocinesia difusa acentuada. Havia insufici&#234;ncia mitral moderada.</p>
    <p>A ultra-sonografia de rins revelou-os de tamanho normal, ambos com 12,1 cm de comprimento; enquanto que o f&#237;gado apresentava esteatose: e havia sinais sugestivos de lit&#237;ase biliar.</p>
    <p>O paciente foi medicado com 40mg de enalapril, 40 mg de furosemida, 25 mg de clortalidona, 5 mg de anlodipina, 500 mg de metildopa, 25 mg de espironolactona, 100 mg de &#225;cido acetilsalic&#237;lico e 1.700 mg de metformina di&#225;rios, al&#233;m de recomenda&#231;&#227;o de dieta pobre em sal, hipocal&#243;rica e para diabete. Com essas medidas o paciente perdeu 28 kg de peso, houve melhora dos sintomas e a press&#227;o arterial reduziu-se para 150/90 mmHg.</p>
    <p>Tr&#234;s anos ap&#243;s pesou 149 kg, a press&#227;o arterial foi 180/130 mmHg.</p>
    <p>O fundo de olho revelou retina com exsudatos em regi&#227;o temporal, cruzamentos arteriovenosos anormais com estase venosa e estreitamento do reflexo arterial, compat&#237;veis com retinopatia hipertensiva</p>
    <p>Os exames laboratoriais (fev 2004) revelaram colesterol 172 mg/dl, HDL-colesterol 41 mg/dl, LDL-colesterol 114 mg/dl, triglic&#233;rides 87 mg/dl, creatinina 1,1 mg/dl, ureia 29 mg/dl e glicemia 126 mg/dl.</p>
    <p>Houve aumento da dose di&#225;ria de metformina para 2.550 mg e da furosemida para 80 mg/dia e foi indicada cirurgia bari&#225;trica.</p>
    <p>Vinha evoluindo pouco sintom&#225;tico at&#233; que em abril de 2006 apresentou s&#237;ncope e ficou internado em hospital pr&#243;ximo &#224; sua resid&#234;ncia e recebeu alta com prescri&#231;&#227;o de 75 mg de captopril, 40 mg de furosemida, 0,25 mg de digoxina, 100 mg de &#225;cido acetilsalic&#237;lico e 5 mg de warfarina. Uma semana ap&#243;s a alta apresentou confus&#227;o mental, disartria, desvio de rima oral para direita e hemiplegia esquerda e foi trazido ao Hospital para atendimento m&#233;dico de emerg&#234;ncia (16 mai 2006).</p>
    <p>O exame f&#237;sico revelou paciente sonolento, Glasgow 12/13, pupilas fotorreagentes e sem sinais de irrita&#231;&#227;o men&#237;ngea, a frequ&#234;ncia de pulso 100 bpm, a press&#227;o arterial 130/80 mmHg e hemiplegia esquerda.</p>
    <p>O eletrocardiograma revelou fibrila&#231;&#227;o atrial, frequ&#234;ncia card&#237;aca m&#233;dia de 142 bpm, com frequentes extrass&#237;stoles ventriculares, prov&#225;vel &#225;rea eletricamente inativa em parede inferior, diminui&#231;&#227;o de for&#231;as septais e de potenciais esquerdos.</p>
    <p>A tomografia de cr&#226;nio revelou hematoma parietoccipital direito e hemorragia subaracnoidea.</p>
    <p>O tempo de protrombina (INR) foi de 12 e foram administradas 5 unidades de plasma fresco gelado e vitamina K 10 mg . Devido &#224; altera&#231;&#227;o da coagula&#231;&#227;o foi indicado tratamento cl&#237;nico com prescri&#231;&#227;o de dexametasona e fenito&#237;na.</p>
    <p>Nova tomografia (18 mai) n&#227;o revelou altera&#231;&#227;o significativa em rela&#231;&#227;o ao exame pr&#233;vio.</p>
    <p>No terceiro dia da interna&#231;&#227;o (19 mai) houve piora do n&#237;vel de consci&#234;ncia e o paciente necessitou intuba&#231;&#227;o orotraqueal para suporte ventilat&#243;rio. Foi novamente cogitada a interven&#231;&#227;o neurocir&#250;rgica.</p>
    <p>Os exames laboratoriais (19 mai) revelaram hemoglobina 11,5 g/dl. Leuc&#243;citos 12.000/mm3, plaquetas 219.000/3, creatinina 0,8 mg/dl, RNI 1,94.</p>
    <p>Foi realizada drenagem de hemorragia intraparenquimatosa (20 mai). O paciente evoluiu com quadro de febre e choque s&#233;ptico, atribu&#237;do a broncopneumonia, pois havia drenagem de secre&#231;&#227;o purulenta pela sonda endotraqueal.</p>
    <p>Apresentou hipertermia (38,5&#176;C) em 20, 21 e 22 maio e foram administrados 4g de cefepime e 1 g vancomicina di&#225;rios a partir de 21 set.</p>
    <p>Foi isolada <italic>Burkholderia cepacia</italic> na hemocultura (21 mai 2006), sens&#237;vel a ceftazidima, meropenen e sulfametoxazol-trimetoprin. Os exames laboratoriais revelaram leucocitose e piora progressiva da fun&#231;&#227;o renal (<xref ref-type="table" rid="t1">Tabela 1</xref>) Apesar do uso de drogas vasoativas e de antibi&#243;ticos n&#227;o houve melhora do quadro. O paciente apresentou parada cardiorrespirat&#243;ria em assistolia n&#227;o responsiva &#224;s medidas de ressuscita&#231;&#227;o, e faleceu (22 mai 2006).</p>
    <table-wrap id="t1">
      <graphic xlink:href="1678-4170-abc-94-02-0282-00023-gt01.jpg"/></table-wrap>
    <p>
      <bold>Aspectos cl&#237;nicos</bold>
    </p>
    <p>O caso relata a hist&#243;ria de um homem de 59 anos, obeso desde a juventude e que aos 44 anos de idade teve o diagn&#243;stico de hipertens&#227;o arterial sist&#234;mica (HAS), quando deu entrada em um servi&#231;o de emerg&#234;ncia com dispneia intensa e press&#227;o arterial de 220x120 mmHg. Devido &#224; m&#225; ader&#234;ncia ao seu tratamento, come&#231;ou a apresentar dispneia aos moderados esfor&#231;os, acompanhada de sudorese profusa e aperto retroesternal. Aos 54 anos, quando foi atendido pela primeira vez no hospital, apresentava-se com IMC 54,1 kg/m&#178;, FC 84 bpm, novamente hipertenso com press&#227;o de 200x110 mmHg e j&#225; manifestava sinais de les&#245;es em &#243;rg&#227;os alvos. Tinha cora&#231;&#227;o dilatado revelado por um &#237;ctus desviado em rela&#231;&#227;o &#224; linha hemiclavicular e palp&#225;vel no 6&#186; espa&#231;o intercostal e sopro sist&#243;lico regurgitativo no foco mitral (+2/4), compat&#237;vel com insufici&#234;ncia mitral. A &#225;rea card&#237;aca era aumentada &#224; radiografia de t&#243;rax (+3/4) e o ecocardiograma transtor&#225;cico mostrava dilata&#231;&#227;o de ventr&#237;culo esquerdo com disfun&#231;&#227;o moderada e hipocinesia difusa e dilata&#231;&#227;o de &#225;trio esquerdo al&#233;m de insufici&#234;ncia mitral moderada, provavelmente secund&#225;ria &#224; dilata&#231;&#227;o card&#237;aca. Tinha les&#227;o renal evidenciada por protein&#250;ria (0,25 g/l) e tr&#234;s anos mais tarde j&#225; apresentava retinopatia hipertensiva caracterizada por exsudatos em regi&#227;o temporal da retina, cruzamentos arteriovenosos anormais com estase venosa e estreitamento do reflexo arterial.</p>
    <p>Os fatores que sugerem que a HAS do paciente acima seja prim&#225;ria s&#227;o: o in&#237;cio tardio da mesma, aos 44 anos, e o fato de que aproximadamente 90% das HAS sejam prim&#225;rias segundo registrado na V Diretriz Brasileira de Hipertens&#227;o Arterial<sup>1</sup> e no <italic>The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure</italic><sup>2</sup>. Por&#233;m na hist&#243;ria cl&#237;nica do paciente existem alguns elementos que obrigatoriamente levam a pensar em causas secund&#225;rias de HAS, como: hipertens&#227;o arterial est&#225;gio tr&#234;s (caracterizada por press&#227;o sist&#243;lica <underline>&gt;</underline> 180 mmHg e/ou press&#227;o diast&#243;lica <underline>&gt;</underline> 110 mmHg) e epis&#243;dios de ronco intenso durante o sono com sensa&#231;&#227;o de sufocamento ao despertar, altamente sugestivo da s&#237;ndrome da apneia/hipopneia do sono, hoje sabidamente causa de HAS secund&#225;ria. Por&#233;m investiga&#231;&#227;o adicional deve ser feita para a confirma&#231;&#227;o deste diagn&#243;stico.</p>
    <p>O paciente, durante sua hist&#243;ria cl&#237;nica, apresentou quadro de dispneia progressiva at&#233; ser desencadeada aos moderados esfor&#231;os, edema de membros inferiores e com ecocardiograma mostrando disfun&#231;&#227;o sist&#243;lica, todos esses, sinais de insufici&#234;ncia card&#237;aca devido &#224; cardiopatia hipertensiva. Corroborando esse diagn&#243;stico temos HAS est&#225;gio tr&#234;s de dif&#237;cil controle, les&#245;es causadas pela HAS em outros &#243;rg&#227;os alvo como rins e retina, al&#233;m da aus&#234;ncia de comprometimento segmentar do ventr&#237;culo esquerdo. Por&#233;m a investiga&#231;&#227;o de doen&#231;a arterial coronariana (DAC) neste paciente foi bastante pobre, n&#227;o sendo poss&#237;vel descartar causa isqu&#234;mica da cardiopatia dilatada. O racional para esta afirma&#231;&#227;o est&#225; no fato dos in&#250;meros fatores de risco que o paciente apresentava para DAC, entre eles: HAS e diabetes melito tipo II, pois segundo o Consenso da Sociedade Brasileira de Diabetes<sup>3</sup>, apresentou duas glicemias de jejum <underline>&gt;</underline> 126 mg/dl (respectivamente 148 mg/dl e 126 mg/dl); apesar de n&#227;o ser dislipid&#234;mico, como na presen&#231;a de diabete, o seu LDL alvo deveria ser pelo menos <underline>&lt;</underline> 100 mg/dl, conforme recomendado pela IV Diretriz Brasileira Sobre Dislipidemia e Preven&#231;&#227;o da Aterosclerose da Sociedade Brasileira de Cardiologia<sup>4</sup>; obesidade grau III (&#237;ndice de massa corp&#243;rea <underline>&gt;</underline> 40 kg/m&#178;) e s&#237;ndrome metab&#243;lica caracterizada nesse caso por: circunfer&#234;ncia abdominal <underline>&gt;</underline> 94 cm, press&#227;o arterial <underline>&gt;</underline> 130x85 mmHg e glicemia de jejum <underline>&gt;</underline> 100 mg/dl de acordo com os crit&#233;rios da Federa&#231;&#227;o Internacional de Diabetes, publicados na IV Diretriz Brasileira Sobre Dislipidemia e Preven&#231;&#227;o da Aterosclerose da Sociedade Brasileira de Cardiologia<sup>4</sup>. Outros comemorativos que refor&#231;am o racional para cardiopatia isqu&#234;mica s&#227;o dados da hist&#243;ria cl&#237;nica tais como aperto retroesternal e dispneia (equivalente isqu&#234;mico); al&#233;m das altera&#231;&#245;es eletrocardiogr&#225;ficas, como a zona eletricamente inativa em parede inferior e a m&#225; progress&#227;o de R na parede anterior.</p>
    <p>Durante a evolu&#231;&#227;o do paciente foi indicada realiza&#231;&#227;o de cirurgia bari&#225;trica. As recomenda&#231;&#245;es atuais para indica&#231;&#227;o deste procedimento que foram publicadas no Consenso Latino Americano de Obesidade<sup>5</sup> s&#227;o: IMC <underline>&gt;</underline> 40 kg/m&#178; ou IMC <underline>&gt;</underline> 35 kg/m&#178; associado a comorbidade como apneia do sono, diabetes melito tipo II, hipertens&#227;o arterial sist&#234;mica, dislipidemia, dificuldade de locomo&#231;&#227;o entre outras. Os pacientes devem ter pelo menos 5 anos de evolu&#231;&#227;o da obesidade, com fracasso dos m&#233;todos convencionais para emagrecimento realizados por profissionais qualificados. Portanto o paciente do caso em quest&#227;o tinha s&#243;lida indica&#231;&#227;o para ser submetido &#224; cirurgia bari&#225;trica.</p>
    <p>Aos 59 anos o paciente teve um epis&#243;dio de s&#237;ncope necessitando de interna&#231;&#227;o hospitalar em outro servi&#231;o. N&#227;o h&#225; relato na hist&#243;ria das caracter&#237;sticas da s&#237;ncope, nem sobre sua investiga&#231;&#227;o, tampouco se houve traumatismo cr&#226;nio-encef&#225;lico. Pelas medica&#231;&#245;es da alta hospitalar provavelmente foi feito o diagn&#243;stico de um primeiro epis&#243;dio de fibrila&#231;&#227;o atrial nesta interna&#231;&#227;o, pois o paciente foi para casa anticoagulado com varfarina e digoxina para poss&#237;vel controle da resposta ventricular. Uma semana ap&#243;s a alta foi trazido novamente ao hospital com quadro neurol&#243;gico compat&#237;vel com acidente vascular cerebral. O eletrocardiograma confirmou o achado de fibrila&#231;&#227;o atrial, al&#233;m de frequ&#234;ncia card&#237;aca m&#233;dia de 142 bpm, frequentes extrass&#237;stoles ventriculares, prov&#225;vel &#225;rea eletricamente inativa em parede inferior, diminui&#231;&#227;o das for&#231;as septais e de potenciais esquerdos. A tomografia de cr&#226;nio mostrou hematoma parietocciptal e hemorragia subaracnoide. O tempo de protrombina na admiss&#227;o estava alargado com INR de 12.</p>
    <p>Este paciente, conforme as Diretrizes para Atendimento de Pacientes com Fibrila&#231;&#227;o Atrial da ACC/AHA<sup>6</sup> , apresentava fibrila&#231;&#227;o atrial persistente (dura&#231;&#227;o <underline>&gt;</underline> 7 dias) e um alto risco para fen&#244;menos tromboemb&#243;licos. Existem v&#225;rios escores que tentam predizer o risco de fen&#244;menos tromboemb&#243;licos em pacientes com fibrila&#231;&#227;o atrial n&#227;o valvar. Um dos mais usados atualmente &#233; o score CHADS2, que d&#225; pontos a cinco fatores de risco para eventos emb&#243;licos, a saber: insufici&#234;ncia card&#237;aca, hipertens&#227;o arterial, idade <underline>&gt;</underline> 75 anos, diabetes, acidente vascular cerebral/ataque isqu&#234;mico transit&#243;rio - os quatro primeiros crit&#233;rios recebem 1 ponto cada e o &#250;ltimo crit&#233;rio 2 pontos. Aceita-se que pacientes com escores <underline>&gt;</underline> 2 devam ser anticoagulados. O escore CHADS2 do paciente em quest&#227;o &#233; de 3 pontos e portanto h&#225; indica&#231;&#227;o formal do uso de antagonista da vitamina K. Por&#233;m, tamb&#233;m &#233; bem documentado na literatura m&#233;dica que a anticoagula&#231;&#227;o com a warfarina aumenta o risco de hemorragia intracraniana em 2 a 5 vezes<sup>7,8</sup>. Metade dos pacientes com sangramento cerebral pela warfarina morrem dentro dos primeiros 30 a 90 dias do evento<sup>9</sup>, mostrando a gravidade desta complica&#231;&#227;o. S&#227;o fatores de alto risco para sangramento cerebral em usu&#225;rios de anticoagulante oral: uso concomitante com AAS, queda com trauma na cabe&#231;a, consumo importante de &#225;lcool, HAS, idade <underline>&gt;</underline> 75 anos, hist&#243;ria de doen&#231;a cerebrovascular, intensidade da anticoagula&#231;&#227;o, angiopatia amil&#243;ide, uso de tabaco e etnia mexicana ou asi&#225;tica<sup>10,11</sup>. Por&#233;m, segundo alguns artigos<sup>12,13</sup>, o risco de hematoma subdural decorrente de queda em pacientes anticoagulados, &#233; t&#227;o pequeno, que pacientes que somem 3 pontos no score de CHADS2 (risco de AVC 5%/ano sem anticoagula&#231;&#227;o) precisariam cair 300 vezes em um ano para que o risco da anticoagula&#231;&#227;o fosse maior que o seu benef&#237;cio.</p>
    <p>O nosso paciente estava recebendo 100mg de AAS em associa&#231;&#227;o a warfarina, era hipertenso, teve uma s&#237;ncope uma semana antes da hemorragia cerebral n&#227;o ficando claro se houve trauma craniano e tinha um INR 12 na admiss&#227;o hospitalar. Portanto apresentava uma s&#233;rie de fatores de risco para sangramento cerebral.</p>
    <p>Postos esses aspectos, quais seriam os mecanismos pelos quais os anticoagulantes aumentam a incid&#234;ncia de sangramento cerebral? Atualmente se sabe que com o passar da idade pequenas arter&#237;olas dentro do c&#233;rebro se fragilizam e se rompem com uma certa frequ&#234;ncia. A maioria das rupturas forma focos de sangramentos autolimitados e subcl&#237;nicos, chamados microssangramentos, que podem ser demonstrados em aut&#243;psias ou pelo uso de sequ&#234;ncias espec&#237;ficas de resson&#226;ncia magn&#233;tica<sup>14</sup>. Este fen&#244;meno &#233; bastante prevalente em hipertensos e em indiv&#237;duos acima dos 75 anos. Ocasionalmente, o vazamento de sangue decorrente desta fragilidade e ruptura arteriolar pode n&#227;o ser contido pelos mecanismos hemost&#225;ticos e pelos tecidos adjacentes e produzir sangramento maior com repercuss&#245;es cl&#237;nicas. Esta &#233; a fisiopatologia da hemorragia intracraniana espont&#226;nea. Os anticoagulantes aumentam a probabilidade de que essas rupturas espont&#226;neas se transformem em sangramentos maiores e com manifesta&#231;&#245;es cl&#237;nicas. Em outras palavras, os anticoagulantes desmascaram os microssangramentos cerebrais assintom&#225;ticos, transformando-os em sangramentos maiores e com cl&#237;nica exuberante. Por isso os fatores de alto risco para sangramento cerebral espont&#226;neo s&#227;o os mesmos para sangramento pelo uso de anticoagulantes<sup>15</sup>.</p>
    <p>Outro fato que chama a aten&#231;&#227;o em rela&#231;&#227;o &#224; hist&#243;ria cl&#237;nica do paciente s&#227;o os elevados n&#237;veis de leptina no sangue. A leptina &#233; um horm&#244;nio secretado pelos adip&#243;citos, que tem a fun&#231;&#227;o de produzir a sensa&#231;&#227;o de saciedade, al&#233;m de participar da regula&#231;&#227;o do balan&#231;o energ&#233;tico corporal. Em 1950, Ingalls e cols.<sup>16</sup> descreveram uma nova esp&#233;cie de ratos obesos mutantes que se caracterizavam por importante hiperfagia e pela diminui&#231;&#227;o no gasto energ&#233;tico. Posteriormente foi descrito que a subst&#226;ncia que n&#227;o era produzida pelos ratos ob/ob, era a leptina. Hoje se sabe que a eleva&#231;&#227;o da leptina s&#233;rica &#233; comum em humanos obesos e caracteriza uma resist&#234;ncia &#224; leptina encontrada nessa popula&#231;&#227;o. Essa eleva&#231;&#227;o se associa com a s&#237;ndrome da resist&#234;ncia insul&#237;nica e portanto com doen&#231;as cardiovasculares.</p>
    <p>Em 1999, S&#246;derberg e cols<sup>17</sup>. descreveram que a leptina plasm&#225;tica est&#225; fortemente associada ao risco aumentado de um primeiro evento de acidente vascular cerebral hemorr&#225;gico, independente de outros marcadores de risco cardiovascular, sendo a leptina um importante elo no desenvolvimento de doen&#231;as cardiovasculares em obesos. Portanto, a resist&#234;ncia &#224; leptina pode ser uma interface da desregula&#231;&#227;o metab&#243;lica com a inflama&#231;&#227;o na patog&#234;nese da obesidade, suas comorbidades e por &#250;ltimo, das doen&#231;as cardiovasculares.</p>
    <p>Ap&#243;s o sangramento cerebral, o paciente, evoluiu com s&#237;ndrome de hipertens&#227;o intracraniana, rebaixamento do n&#237;vel de consci&#234;ncia e necessidade de intuba&#231;&#227;o orotraqueal. Ap&#243;s a drenagem da hemorragia intraparenquimatosa evoluiu com pneumonia associada &#224; ventila&#231;&#227;o mec&#226;nica, caracterizada por secre&#231;&#227;o purulenta pela c&#226;nula, febre e leucocitose. A incid&#234;ncia de pneumonia associada &#224; ventila&#231;&#227;o mec&#226;nica descrita pela literatura &#233; de 3%/dia na primeira semana de intuba&#231;&#227;o, 2%/dia na segunda e 1%/dia na terceira semana<sup>18</sup>, portanto constitui complica&#231;&#227;o bastante frequente. No dia 20 de maio de 2006 o paciente encontrava-se em choque s&#233;ptico, devido &#224; pneumonia por <italic>Burkholderia cepacia</italic>, evoluindo rapidamente para disfun&#231;&#227;o de m&#250;ltiplos &#243;rg&#227;os e morte no dia 22 de maio de 2006.</p>
    <p>
      <bold>Dr. Pedro Veronese</bold>
    </p>
    <p>
      <bold>Hip&#243;teses diagn&#243;sticas</bold>
    </p>
    <p>Obesidade grau III; HAS prim&#225;ria e/ou secund&#225;ria a poss&#237;vel s&#237;ndrome da apneia/hipopneia do sono; Diabetes mellitus tipo II; s&#237;ndrome metab&#243;lica; hipotireoidismo subcl&#237;nico; retinopatia hipertensiva; cardiopatia dilatada hipertensiva e/ou isqu&#234;mica; fibrila&#231;&#227;o atrial cr&#244;nica persistente; intoxica&#231;&#227;o warfar&#237;nica; s&#237;ndrome hemorr&#225;gica cerebral: hematoma intraparenquimatoso e hemorragia subaracn&#243;ide com s&#237;ndrome de hipertens&#227;o intracraniana; e choque s&#233;ptico por pneumonia hospitalar devido a <italic>B. cepacia</italic></p>
    <p>
      <bold>Dr. Pedro Veronese</bold>
    </p>
    <p>
      <bold>Necr&#243;psia</bold>
    </p>
    <p>Cad&#225;ver de paciente apresentando acentuada obesidade, notando-se incis&#227;o cir&#250;rgica recente de craniotomia temporoparietal direita. O cora&#231;&#227;o era volumoso e pesou 866 g. Apresentava hipertrofia e dilata&#231;&#227;o das quatro c&#226;maras, com m&#250;ltiplos pequenos focos de fibrose intersticial em ambos os ventr&#237;culos (<xref ref-type="fig" rid="f2">Figura 2</xref>). Havia vegeta&#231;&#245;es na face atrial da c&#250;spide posterior da valva mitral, medindo 1,5cm de extens&#227;o, e nas semilunares da valva pulmonar (a maior medindo 0,8cm), notando-se ao exame histol&#243;gico a presen&#231;a de numerosas col&#244;nias de cocos Gram positivos (<xref ref-type="fig" rid="f3">Figura 3</xref>). As valvas card&#237;acas n&#227;o apresentavam sequela de doen&#231;a reum&#225;tica ou evid&#234;ncia de quaisquer altera&#231;&#245;es anatomopatol&#243;gicas pr&#233;vias. As coron&#225;rias epic&#225;rdicas apresentavam aterosclerose discreta, assim como a aorta, n&#227;o havendo les&#245;es obstrutivas. Havia microabscessos e col&#244;nias bacterianas no mioc&#225;rdio, rins e ba&#231;o, com infartos macrosc&#243;picos focais nesses dois &#250;ltimos &#243;rg&#227;os (<xref ref-type="fig" rid="f4">Figura 4</xref>). O enc&#233;falo pesou 1.428g, havendo edema do hemisf&#233;rio cerebral direito, ademais de extenso infarto hemorr&#225;gico acometendo c&#243;rtex e subst&#226;ncia branca desse lado e hemorragia nos ventr&#237;culos laterais (<xref ref-type="fig" rid="f5">Figura 5</xref>). A pesquisa histoqu&#237;mica de bact&#233;rias foi negativa nesse &#243;rg&#227;o. Os pulm&#245;es apresentavam congest&#227;o, edema e &#225;reas de ac&#250;mulo de macr&#243;fagos contendo pigmento hemossider&#243;tico nos espa&#231;os alveolares. O f&#237;gado apresentava dilata&#231;&#227;o sinusoidal centrolobular, com &#225;reas de necrose hemorr&#225;gica recente. Os rins apresentavam focos de esclerose glomerular e fibrose intersticial. Havia grandes c&#225;lculos esverdeados na ves&#237;cula biliar, medindo de 1 a 2 cm cada.</p>
    <fig id="f2">
      <graphic xlink:href="1678-4170-abc-94-02-0282-00023-gf02.jpg"/></fig>
    <fig id="f3">
      <graphic xlink:href="1678-4170-abc-94-02-0282-00023-gf03.jpg"/></fig>
    <fig id="f4">
      <graphic xlink:href="1678-4170-abc-94-02-0282-00023-gf04.jpg"/></fig>
    <fig id="f5">
      <graphic xlink:href="1678-4170-abc-94-02-0282-00023-gf05.jpg"/></fig>
    <p>
      <bold>Dr. Luiz Alberto Benvenuti</bold>
    </p>
    <p>
      <bold>Diagn&#243;sticos anatomopatol&#243;gicos</bold>
    </p>
    <p>Obesidade m&#243;rbida; hipertens&#227;o arterial sist&#234;mica; diabetes mellitus; calculose da ves&#237;cula biliar; cardiopatia hipertensiva em fase dilatada; endocardite infecciosa das valvas mitral e pulmonar; infarto cerebral hemorr&#225;gico; septicemia (causa do &#243;bito).</p>
    <p>
      <bold>Dr. Luiz Alberto Benvenuti</bold>
    </p>
    <p>
      <bold>Coment&#225;rios</bold>
    </p>
    <p>Caso de homem de 59 anos de idade, apresentando como doen&#231;a principal a obesidade m&#243;rbida, acompanhada de hipertens&#227;o arterial sist&#234;mica, diabetes mellitus e calculose da ves&#237;cula biliar, comorbidades frequentemente a ela associadas<sup>19</sup>. A hipertens&#227;o era de dif&#237;cil controle e o paciente evoluiu com cardiopatia hipertensiva descompensada e insufici&#234;ncia card&#237;aca congestiva progressiva. Apesar da exist&#234;ncia de fatores de risco, n&#227;o desenvolveu aterosclerose significativa em nenhum territ&#243;rio arterial, e n&#227;o havia coronariopatia. A causa do &#243;bito foi septicemia bacteriana secund&#225;ria &#224; endocardite infecciosa das valvas mitral e pulmonar, por cocos Gram positivos. A bact&#233;ria <italic>Burkholderia cepacia</italic>, identificada na hemocultura pouco antes do &#243;bito &#233; agente Gram negativo, e portanto n&#227;o imputamos &#224; mesma a etiologia da endocardite. Al&#233;m do comprometimento simult&#226;neo da valva pulmonar, outro aspecto n&#227;o habitual &#233; que ambas as valvas acometidas (mitral e pulmonar) eram previamente normais, ou seja, n&#227;o apresentavam sequela de doen&#231;a anterior. A manifesta&#231;&#227;o cl&#237;nica inicial da endocardite foi neurol&#243;gica, devido ao extenso infarto cerebral hemorr&#225;gico de prov&#225;vel natureza emb&#243;lica. Na necr&#243;psia encontramos indiscut&#237;veis evid&#234;ncias de emboliza&#231;&#227;o s&#233;ptica, com presen&#231;a de microabscessos e col&#244;nias bacterianas no ba&#231;o, rins e mioc&#225;rdio. Apesar do diabetes mellitus ser genericamente considerado fator predisponente para infec&#231;&#227;o, o mesmo n&#227;o tem sido classicamente considerado como fator de risco para o desenvolvimento de endocardite infecciosa. Entretanto, esse conceito tem se modificado mais recentemente, devido a relatos de associa&#231;&#227;o entre essas duas entidades, como no presente caso, e da maior gravidade da endocardite em pacientes diab&#233;ticos dependentes de insulina<sup>20, 21</sup>.</p>
    <p>
      <bold>Dr. Luiz Alberto Benvenuti</bold>
    </p>
    <p>
      <fn id="back" fn-type="corresp">
        <p>Correspond&#234;ncia:</p>
        <p> Vera D. Aiello </p>
        <p> InCor - Av. Dr. En&#233;as de Carvalho Aguiar, 44 </p>
        <p> 05403-000 - S&#227;o Paulo, SP </p>
        <p> E-mail: </p>
        <p>
          <email xlink:href="anpvera@incor.usp.br">anpvera@incor.usp.br</email>
        </p>
      </fn>
    </p>
    <p><bold>Editor da Se&#231;&#227;o:</bold> Alfredo Jos&#233; Mansur (<email xlink:href="ajmansur@incor.usp.br">ajmansur@incor.usp.br</email>) </p>
    <p><bold>Editores Associados:</bold> Desid&#233;rio Favarato (<email xlink:href="dclfavarato@incor.usp.br">dclfavarato@incor.usp.br</email>) </p>
    <p> Vera Demarchi Aiello (<email xlink:href="anpvera@incor.usp.br">anpvera@incor.usp.br</email>)</p>
  </body>
  <back>
    <ref-list>
      <ref id="B1">
        <mixed-citation>1. Mion Jr D, Kohlmann    Jr O, Machado CA, Amodeo C, Gomes MAM, Praxedes JN, et al. V Diretrizes brasileiras    de hipertens&#227;o arterial/Sociedade Brasileira de Cardiologia/ Sociedade    Brasileira de Hipertens&#227;o/ Sociedade Brasileira de Nefrologia. Portal    Cardiol. [Acesso em 2008 set 10]. Dispon&#237;vel em : <ext-link ext-link-type="uri" xlink:href="http://www.bvsms.saude.gov.br/bvs/publica%E7%F5es/v-diretrizes">http:WWW.bvsms.saude.gov.br/bvs/publica&#231;&#245;es/v-diretrizes</ext-link></mixed-citation>
        <element-citation publication-type="confproc">
          <person-group person-group-type="author">
            <name>
              <surname>Mion Jr</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Kohlmann Jr</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Machado</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>Amodeo</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Gomes</surname>
              <given-names>MAM</given-names>
            </name>
            <name>
              <surname>Praxedes</surname>
              <given-names>JN</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B2">
        <mixed-citation>2. Chobanian AC,    Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, et al. The Seventh Report    f the Joint National Committee on Prevention, Detection, Evaluation, and Treatment    of High Blood Pressure. Hypertension 2003;42(6):1206-52.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>The Seventh Report f the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure</article-title>
          <source>Hypertension</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>1206</fpage>
          <lpage>52</lpage>
          <issue>6</issue>
          <volume>42</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Chobanian</surname>
              <given-names>AC</given-names>
            </name>
            <name>
              <surname>Bakris</surname>
              <given-names>GL</given-names>
            </name>
            <name>
              <surname>Black</surname>
              <given-names>HR</given-names>
            </name>
            <name>
              <surname>Cushman</surname>
              <given-names>WC</given-names>
            </name>
            <name>
              <surname>Green</surname>
              <given-names>LA</given-names>
            </name>
            <name>
              <surname>Izzo</surname>
              <given-names>JL</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B3">
        <mixed-citation>3. Diagn&#243;stico    e Classifica&#231;&#227;o do Diabetes Melito e Tratamento do Diabetes Melito    Tipo 2. Recomenda&#231;&#245;es da Sociedade Brasileira de Diabetes. Arq    Bras Endocrinol Metab. 2000;44 (4 supl. 1):5-22.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Recomenda&#231;&#245;es da Sociedade Brasileira de Diabetes</article-title>
          <source>Arq Bras Endocrinol Metab</source>
          <date>
            <year>2000</year>
          </date>
          <fpage>5</fpage>
          <lpage>22</lpage>
          <issue>4</issue>
          <volume>44</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Diagn&#243;stico e Classifica&#231;&#227;o do Diabetes Melito e Tratamento do Diabetes Melito Tipo</surname>
              <given-names>2</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B4">
        <mixed-citation>4. Sposito AC,    Caramelli B, Fonseca FAH, Bertolami MC (Coordenadores). IV Diretriz Brasileira    Sobre Dislipidemia e Preven&#231;&#227;o da Aterosclerose do Departamento    de Aterosclerose da Sociedade Brasileira de Cardiologia. Arq Bras Cardiol. 2007;88    (supl. 1): 2-19.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>IV Diretriz Brasileira Sobre Dislipidemia e Preven&#231;&#227;o da Aterosclerose do Departamento de Aterosclerose da Sociedade Brasileira de Cardiologia</article-title>
          <source>Arq Bras Cardiol</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>2</fpage>
          <lpage>19</lpage>
          <volume>88</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Sposito</surname>
              <given-names>AC</given-names>
            </name>
            <name>
              <surname>Caramelli</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Fonseca</surname>
              <given-names>FAH</given-names>
            </name>
            <name>
              <surname>Bertolami</surname>
              <given-names>MC</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B5">
        <mixed-citation>5. Coutinho, W.    Consenso Latino Americano de Obesidade. Arq Bras Endocrinol Metab. 1999;43:21-67.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Consenso Latino Americano de Obesidade</article-title>
          <source>Arq Bras Endocrinol Metab</source>
          <date>
            <year>1999</year>
          </date>
          <fpage>21</fpage>
          <lpage>67</lpage>
          <volume>43</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Coutinho</surname>
              <given-names>W.</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B6">
        <mixed-citation>6. Fuster V, Ryden    LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA et al. ACC/AHA/ESC 2006 Guidelines    for the Management of Patients With Atrial Fibrillation.executive summary :    a report of the American College of Cardiology/ AHA/Task Force on practice guidelines    and the European Society of Cardiology Committee for Practice Guidelines. J    Am Coll Cardiol. 2006;48(4):149-246</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation: executive summary : a report of the American College of Cardiology/ AHA/Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines</article-title>
          <source>J Am Coll Cardiol</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>149</fpage>
          <lpage>246</lpage>
          <issue>4</issue>
          <volume>48</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Fuster</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Ryden</surname>
              <given-names>LE</given-names>
            </name>
            <name>
              <surname>Cannom</surname>
              <given-names>DS</given-names>
            </name>
            <name>
              <surname>Crijns</surname>
              <given-names>HJ</given-names>
            </name>
            <name>
              <surname>Curtis</surname>
              <given-names>AB</given-names>
            </name>
            <name>
              <surname>Ellenbogen</surname>
              <given-names>KA</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B7">
        <mixed-citation>7. Hart RG, Boop    BS, Anderson DC. Oral anticoagulants and intracranial hemorrhage:facts and hypotheses.    Stroke. 1995;26:1471-7.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Oral anticoagulants and intracranial hemorrhage: facts and hypotheses</article-title>
          <source>Stroke</source>
          <date>
            <year>1995</year>
          </date>
          <fpage>1471</fpage>
          <lpage>7</lpage>
          <volume>26</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Hart</surname>
              <given-names>RG</given-names>
            </name>
            <name>
              <surname>Boop</surname>
              <given-names>BS</given-names>
            </name>
            <name>
              <surname>Anderson</surname>
              <given-names>DC</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B8">
        <mixed-citation>8. Rosand J, Eckman    MH, Knudsen KA, Singer DE, Greenberg SM. The effect of warfarin and intensity    of anticoagulation on outcome of intracerebral hemorrhage. Arch Intern Med.    2004;164(8):880-4.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>The effect of warfarin and intensity of anticoagulation on outcome of intracerebral hemorrhage</article-title>
          <source>Arch Intern Med</source>
          <date>
            <year>2004</year>
          </date>
          <fpage>880</fpage>
          <lpage>4</lpage>
          <issue>8</issue>
          <volume>164</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Rosand</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Eckman</surname>
              <given-names>MH</given-names>
            </name>
            <name>
              <surname>Knudsen</surname>
              <given-names>KA</given-names>
            </name>
            <name>
              <surname>Singer</surname>
              <given-names>DE</given-names>
            </name>
            <name>
              <surname>Greenberg</surname>
              <given-names>SM</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B9">
        <mixed-citation>9. Sjoblom L, Hardemark    HG, Lindgren A, Norrving B, Fahlen M, Samuelssom M et al. Management and prognostic    features of intracerebral hemorrhage during anticoagulant therapy: a Swedish    multicenter study. Stroke. 2001;32(11):2567-74</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Management and prognostic features of intracerebral hemorrhage during anticoagulant therapy: a Swedish multicenter study</article-title>
          <source>Stroke</source>
          <date>
            <year>2001</year>
          </date>
          <fpage>2567</fpage>
          <lpage>74</lpage>
          <issue>11</issue>
          <volume>32</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Sjoblom</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Hardemark</surname>
              <given-names>HG</given-names>
            </name>
            <name>
              <surname>Lindgren</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Norrving</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Fahlen</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Samuelssom</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B10">
        <mixed-citation>10. Hart RG, Tonarelli    SB, Pearce LA. Avoiding central nervous system bleeding during antithrombotic    therapy: Recent data and ideas. Stroke 2005;36(7):1588-93.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Avoiding central nervous system bleeding during antithrombotic therapy: Recent data and ideas</article-title>
          <source>Stroke</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>1588</fpage>
          <lpage>93</lpage>
          <issue>7</issue>
          <volume>36</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Hart</surname>
              <given-names>RG</given-names>
            </name>
            <name>
              <surname>Tonarelli</surname>
              <given-names>SB</given-names>
            </name>
            <name>
              <surname>Pearce</surname>
              <given-names>LA</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B11">
        <mixed-citation>11. Hart RG, Benavente    O, Pearce LA. Increased risk of intracranial hemorrhage when aspirin is combined    with warfarin: A meta-analysis and hypothesis. Cerebrovasc Dis. 1999;9(4):215-7.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Increased risk of intracranial hemorrhage when aspirin is combined with warfarin: A meta-analysis and hypothesis</article-title>
          <source>Cerebrovasc Dis</source>
          <date>
            <year>1999</year>
          </date>
          <fpage>215</fpage>
          <lpage>7</lpage>
          <issue>4</issue>
          <volume>9</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Hart</surname>
              <given-names>RG</given-names>
            </name>
            <name>
              <surname>Benavente</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Pearce</surname>
              <given-names>LA</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B12">
        <mixed-citation>12. Man-Son-Hing    M, Laupacis A. Anticoagulant-related bleeding in older persons with atrial fibrillation:    physicians fear often unfounded. Arch Intern Med. 2003;163(13):1580-6.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Anticoagulant-related bleeding in older persons with atrial fibrillation: physicians fear often unfounded</article-title>
          <source>Arch Intern Med</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>1580</fpage>
          <lpage>6</lpage>
          <issue>13</issue>
          <volume>163</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Man-Son-Hing</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Laupacis</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B13">
        <mixed-citation>13. Man-Son-Hing    M, Nichol G. Choosing antithrombotic therapy for elderly patients with atrial    fibrillation who are at risk for fall. Arch Intern Med. 1999;159(7):677-85.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for fall</article-title>
          <source>Arch Intern Med</source>
          <date>
            <year>1999</year>
          </date>
          <fpage>677</fpage>
          <lpage>85</lpage>
          <issue>7</issue>
          <volume>159</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Man-Son-Hing</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Nichol</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B14">
        <mixed-citation>14. Roob G, Schmidt    R, Kapeller P, Lechner A, Hartung HP, Fazekas F. MRI evidence of past cerebral    microbleeds in a healthy elderly population. Neurology. 1999:52(5);991-4.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>MRI evidence of past cerebral microbleeds in a healthy elderly population</article-title>
          <source>Neurology</source>
          <date>
            <year>1999</year>
          </date>
          <fpage>52(5);991</fpage>
          <lpage>4</lpage>
          <person-group person-group-type="author">
            <name>
              <surname>Roob</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Schmidt</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Kapeller</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Lechner</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Hartung</surname>
              <given-names>HP</given-names>
            </name>
            <name>
              <surname>Fazekas</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B15">
        <mixed-citation>15. Fang MC. Age    and the risk of warfarin-associated hemorrhage: the anticoagulation and risk    factors in atrial fibrillation study. J Am Geriatr Soc. 2006:54(8);1231-6.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Age and the risk of warfarin-associated hemorrhage: the anticoagulation and risk factors in atrial fibrillation study</article-title>
          <source>J Am Geriatr Soc</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>54(8);1231</fpage>
          <lpage>6</lpage>
          <person-group person-group-type="author">
            <name>
              <surname>Fang</surname>
              <given-names>MC</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B16">
        <mixed-citation>16. Martin S, Qasim    A, Reilly M. Leptin Resistance. J Am Coll Cardiol. 2008;52(15):1201-10.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Leptin Resistance</article-title>
          <source>J Am Coll Cardiol</source>
          <date>
            <year>2008</year>
          </date>
          <fpage>1201</fpage>
          <lpage>10</lpage>
          <issue>15</issue>
          <volume>52</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Martin</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Qasim</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Reilly</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B17">
        <mixed-citation>17. S&#246;derberg    S, Ahr&#233;n B, Stegmayr B, Johnson O, Wiklund PG, Weinehall L et al. Leptin    Is a Risk Marker for First-Ever Hemorrhagic Stroke in a Population-Based Cohort.    Stroke. 1999;3(2):328-37</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Leptin Is a Risk Marker for First-Ever Hemorrhagic Stroke in a Population-Based Cohort</article-title>
          <source>Stroke</source>
          <date>
            <year>1999</year>
          </date>
          <fpage>328</fpage>
          <lpage>37</lpage>
          <issue>2</issue>
          <volume>3</volume>
          <person-group person-group-type="author">
            <name>
              <surname>S&#246;derberg</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Ahr&#233;n</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Stegmayr</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Johnson</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Wiklund</surname>
              <given-names>PG</given-names>
            </name>
            <name>
              <surname>Weinehall</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B18">
        <mixed-citation>18. Porzecanski    I, Bowton DL. Diagnosis and Treatment of Ventilator-Associated Pneumonia. CHEST.    2006;130:597-604</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Diagnosis and Treatment of Ventilator-Associated Pneumonia</article-title>
          <source>CHEST</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>597</fpage>
          <lpage>604</lpage>
          <volume>130</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Porzecanski</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Bowton</surname>
              <given-names>DL</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B19">
        <mixed-citation>19. Bray GA. Health    hazards of obesity. Endocrinol Metab Clin North Am. 1996;25(4):907-19.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Health hazards of obesity</article-title>
          <source>Endocrinol Metab Clin North Am</source>
          <date>
            <year>1996</year>
          </date>
          <fpage>907</fpage>
          <lpage>19</lpage>
          <issue>4</issue>
          <volume>25</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Bray</surname>
              <given-names>GA</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B20">
        <mixed-citation>20. Movahed MR,    Hashemzadeh M, Jamal MM. Increased prevalence of infectious endocarditis in    patients with type II diabetes mellitus. J Diabetes Complications. 2007;21(6):403-6.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Increased prevalence of infectious endocarditis in patients with type II diabetes mellitus</article-title>
          <source>J Diabetes Complications</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>403</fpage>
          <lpage>6</lpage>
          <issue>6</issue>
          <volume>21</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Movahed</surname>
              <given-names>MR</given-names>
            </name>
            <name>
              <surname>Hashemzadeh</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Jamal</surname>
              <given-names>MM</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B21">
        <mixed-citation>21. Duval X, Alla    F, Doco-Lecompte T, Le Moing V, Delahaye F, Mainardi JL et al. Diabetes mellitus    and infective endocarditis: the insulin factor in patient morbidity and mortality.    Eur Heart J. 2007;28(1):59-64.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Diabetes mellitus and infective endocarditis: the insulin factor in patient morbidity and mortality</article-title>
          <source>Eur Heart J</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>59</fpage>
          <lpage>64</lpage>
          <issue>1</issue>
          <volume>28</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Duval</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Alla</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Doco-Lecompte</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Le Moing</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Delahaye</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Mainardi</surname>
              <given-names>JL</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <sub-article article-type="translation" id="TRen" xml:lang="en">
    <front-stub>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title xml:lang="en">Case 1 - 59-year-old male patient with severe obesity, arterial hypertension and heart failure submitted to anticoagulation therapy for atrial fibrillation, presented cerebrovascular accident and septicemia</article-title>
      </title-group>
    </front-stub>
    <body>
      <p>
        <bold>ANATOMOCLINICAL CORRELATION</bold>
      </p>
      <p>
        <fn id="top-body2">
          <label>
            <bold>Case 1 - 59-year-old male patient with severe obesity, arterial hypertension and heart failure submitted to anticoagulation therapy for atrial fibrillation, presented cerebrovascular accident and septicemia</bold>
          </label>
          <p>
            <bold>Pedro Veronese; Luiz Alberto Benvenuti</bold>
          </p>
        </fn>
      </p>
      <p>Instituto do Cora&#231;&#227;o (InCor) HC-FMUSP, S&#227;o Paulo</p>
      <p>Correspond&#234;ncia</p>
      <p><bold>Key words:</bold> Obesity; hypertension; heart failure; stroke; sepsis.</p>
      <p>A 59-year-old obese male patient was admitted at the hospital with left hemiplegia. He had been first admitted at the age of 54, due to intense dyspnea and arterial hypertension.</p>
      <p>He was diagnosed with arterial hypertension at 44 years, when he presented intense dyspnea and arterial hypertension with blood pressure (BP) levels of 220/120 mm Hg. He sought emergency medical care and was medicated. The patient evolved with dyspnea, intense sudoresis and retrosternal pressure, triggered by moderate exertion. His adherence to treatment was irregular. He started to present episodes of intense snoring during sleep and a sensation of suffocation upon awakening. The patient knew he had been obese since a young age, but his weight had progressively increased since the age of 48 years.</p>
      <p>At physical examination (March 12, 2001) his weight was 163.8 kg, height 1.74 m, body mass index was 54.1 kg/m<sup>2</sup>, pulse of 84 bpm, BP 200/110 mm Hg. Pulmonary assessment was normal. The ictus cordis was palpable at the 6<sup>th</sup> intercostal space, out of the left hemiclavicular line and the auscultation did not disclose any extra heart sounds. There was a systolic murmur ++/4+ in the mitral area and left sternal border. The abdomen was large and he presented an "abdominal apron", without visceromegaly. He presented slight lower-limb edema and decreased pulses in the lower limbs.</p>
      <p>The chest X-ray (March 7, 2001) showed cardiomegaly +++/4+ with global heart increase. The electrocardiogram (ECG) (March 7, 2001) showed sinus rhythm, heart rate of 77 bpm, PR interval of 172 ms, QRS duration of 96 ms, QT interval of 372 ms, a QRS axis shifted (-30<sup>0</sup>), initial notch with QS III wave and aVF, nonprogressive R wave from V1 to V3 and loss of potential in the left leads (<xref ref-type="fig" rid="en_23f01-body2">Figure 1</xref>).</p>
      <p content-type="asset">
        <fig id="en_23f01-body2">
          <graphic xlink:href="1678-4170-abc-94-02-0282-00023-gf01-en.jpg"/></fig>
      </p>
      <p>Laboratory assessment (March 8, 2001) showed hemoglobin = 14.4 g/dL, hematocrit = 43%, uric acid = 9 mg/dL, creatinine = 1.6 mg/dL, potassium = 4.4 mEq/L, sodium =145 mEq/L, fasting glycemia = 148 mg/dL, total cholesterol = 121 mg/dL, triglycerides = 57 mg/dL; urinalysis showed proteinuria of 0.25 g/L, with no other alterations. TSH was 5.28 U/mL, free T4 was 1.1 ng/dL, leptin was 31 ng/mL (normal range =3.8&#177;1.8 ng/mL), testosterone = 336 ng/mL, FSH = 2.6 UI/L, LH = 2.0 UI/L, estradiol = 40.2 pg/mL, insulin = 7.9 Ul/mL, urinary cortisol = 261 g/24 h and DHEAS = 1457 ng/mL.</p>
      <p>The echocardiogram (April 26, 2001) showed septum and posterior wall thickness of 10 mm, aortic diameter of 32 mm, left atrial diameter of 52 mm, left ventricular (LV) diastolic diameter of 70 mm and LV systolic diameter of 57 mm, with ejection fraction of 46%, due to accentuated diffuse hypokinesis. The patient presented moderate mitral regurgitation.</p>
      <p>The kidney ultrasonography disclosed normal-sized kidneys, both with 12.1 cm in length, whereas the liver showed signs of steatosis; there were signs suggestive of cholelithiasis.</p>
      <p>The patient was medicated with 40 mg of enalapril, 40 mg of furosemide, 25 mg of chlorthalidone, 5 mg of amlodipine, 500 mg of methyldopa, 25 mg of spironolactone, 100 mg of acetylsalicylic acid and 1,700 mg of metformin daily, in addition to dietary recommendations of a low-salt, low-calorie diet for type II diabetes. The patient's adherence to treatment, together with dietary changes, resulted in a weight loss of 28 kg, symptom improvement and BP decrease to 150/90 mm Hg.</p>
      <p>Three years later the patient weighed 149 kg and the BP was 180/130 mm Hg.</p>
      <p>The fundoscopy showed retinal exudates in the temporal region, abnormal arteriovenous crossings with venous stasis and arterial reflex narrowing, compatible with hypertensive retinopathy.</p>
      <p>Laboratory assessment (February 2004) showed cholesterol = 172 mg/dL, HDL-cholesterol = 41 mg/dL, LDL-cholesterol = 114 mg/dL, triglycerides = 87 mg/dL, creatinine = 1.1 mg/dL, urea = 29 mg/dL and glycemia = 126 mg/dL.</p>
      <p>The metformin dose was increased to 2550 mg and the furosemide dose to 80 mg/day; the patient was then referred to bariatric surgery.</p>
      <p>The patient evolved with few symptoms until April 2006, when he presented syncope and was admitted at the hospital close to his home; he was released with a prescription for 75 mg of captopril, 40 mg of furosemide, 0.25 mg of digoxin, 100 mg of acetylsalicylic acid and 5 mg of warfarin. One week after hospital release he started to present mental confusion, dysarthria, mouth deviation to the right and left hemiplegia and was brought to the hospital for emergency medical treatment (May 16, 2006).</p>
      <p>The physical examination disclosed a sleepy patient, Glasgow 12/13, reactive pupils and no signs of meningeal irritation, with pulse rate of 100 bpm, BP of 130/80 mm Hg and left hemiplegia.</p>
      <p>The ECG showed atrial fibrillation, mean heart rate of 142 bpm, with frequent ventricular extrasystoles, probable electrically inactive area on the inferior wall, decreased septal strength and left potential. The skull tomography revealed right parietooccipital hematoma and subarachnoid hemorrhage.</p>
      <p>The prothrombin time (INR) was 12 and 5 units of fresh-frozen plasma were administered together with vitamin K (10 mg). Due to the coagulation alteration, a clinical treatment with dexamethasone and phenytoin was prescribed.</p>
      <p>A new tomography (May 18) did not disclose significant alterations when compared to the previous examination.</p>
      <p>On the third day of hospitalization (May 19), the patient presented worsening of the level of consciousness and the patient required orotracheal intubation for ventilator support. The neurosurgical intervention was considered once more.</p>
      <p>The laboratory assessment (May 19) showed hemoglobin = 11.5 g/dL, leukocytes = 12000/mm3, platelets = 219000/3, creatinine = 0.8 mg/dL, INR = 1.94.</p>
      <p>The patient was then submitted to intraparenchymatous hemorrhage drainage (May 20). The patient started to present fever and septic shock, attributed to bronchopneumonia, as a purulent secretion was drained through the endotracheal tube.</p>
      <p>The patient presented fever (38.5&#176;C) on May 20, 21 and 22 and received 4g of cefepime and 1 g of vancomycin daily from September 21 on.</p>
      <p><italic>Burkholderia cepacia</italic> was isolated from the blood culture (May 21, 2006), which was sensitive to ceftazidime, meropenem and sulfametoxazol/trimetoprim. The laboratory assessment disclosed leukocytosis and progressive worsening in renal function (<xref ref-type="table" rid="t1-body2">Table 1</xref>). In spite of the use of vasoactive drugs and antibiotics, the patient did not improve and presented cardiorespiratory arrest in asystole, non-responsive to resuscitation maneuvers and died on May 22, 2006.</p>
      <table-wrap id="t1-body2">
        <graphic xlink:href="1678-4170-abc-94-02-0282-00023-gt01-en.jpg"/></table-wrap>
      <p>
        <bold>Clinical aspects</bold>
      </p>
      <p>The present case reports on a 59-year-old male patient who had been obese since a young age and received a diagnosis of systemic arterial hypertension (SAH) at the age of 44 years, when he was admitted at the emergency service with intense dyspnea and BP of 220x120 mm Hg. Due to low treatment adherence, he started to present dyspnea at moderate exertion, accompanied by intense sudoresis and retrosternal pressure. At 54, when he was first admitted at the hospital, he presented a BMI of 54.1 kg/m&#178;, HR of 84 bpm, was once again hypertensive, with a BP of 200x110 mmHg and presented evidence of target-organ damage. He presented a dilated heart, disclosed by deviation of the ictus cordis in relation to the hemiclavicular line, palpable at the 6<sup>th</sup> intercostal space and a mitral regurgitation systolic murmur (+2/4). The cardiac area was enlarged at the chest X-ray (+3/4) and the transthoracic echocardiogram showed left ventricular dilatation with moderate dysfunction and diffuse hypokinesia and left atrial dilatation in addition to moderate mitral regurgitation, probably secondary to cardiac dilatation. Kidney damage was evidenced by proteinuria (0.25 g/L) and three years later the patient already presented hypertensive retinopathy characterized by retinal exudates in the temporal region, abnormal arteriovenous crossings with venous stasis and arterial reflex narrowing.</p>
      <p>The factors that suggest that the patient's SAH was primary are: the late onset of the SAH, at 44 years and the fact that approximately 90% of the SAH cases are primary, according to the V Brazilian Guidelines of Arterial Hypertension<sup>1</sup> and The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure<sup>2</sup>. However, the patient's clinical history presents some elements that obligatorily suggest secondary causes of SAH, such as stage III arterial hypertension (characterized by systolic pressure <underline>&gt;</underline> 180 mm Hg and/or diastolic pressure <underline>&gt;</underline> 110 mm Hg) and episodes of intense snoring during sleep and a sensation of suffocation upon awakening, highly suggestive of sleep apnea/hypopnea syndrome, currently a known cause of secondary SAH. Nevertheless, an additional investigation must be carried out to confirm this diagnosis.</p>
      <p>The patient, during his clinical history, presented a progressive dyspnea condition, until it was triggered by moderate exertion, as well as lower-limb edema and the echocardiogram showed systolic dysfunction; all of these signs suggested heart failure due to hypertensive cardiopathy. Corroborating this diagnosis, he presented stage III SAH that was difficult to control, SAH-related injuries in other target-organs, such as kidneys and retina, in addition to the absence of LV segmental involvement. However, the investigation of coronary artery disease (CAD) in this patient was quite deficient and it was not possible to rule out ischemia-related dilated cardiopathy. The reasoning for this statement is the fact that the patient presented many risk factors for CAD, among them: SAH and type II diabetes mellitus, as, according to the Consensus of the Brazilian Society of Diabetes<sup>3</sup> he presented two fasting glycemia levels <underline>&gt;</underline> 126 mg/dL (respectively, 148 mg/dL and 126 mg/dL); although he was not dyslipidemic, in the presence of diabetes his target-LDL should be at least <underline>&lt;</underline> 100 mg/dL, as recommended by the IV Brazilian Guideline on Dyslipidemia and Atherosclerosis Prevention of the Brazilian Society of Cardiology<sup>4</sup>; grade III obesity (body mass index <underline>&gt;</underline> 40 kg/m&#178;) and metabolic syndrome, in this case characterized by: abdominal circumference <underline>&gt;</underline> 94 cm, BP <underline>&gt;</underline> 130x85 mmHg and fasting glycemia <underline>&gt;</underline> 100 mg/dL, according to the criteria of the International Federation of Diabetes, published at the IV Brazilian Guideline on Dyslipidemia and Atherosclerosis Prevention of the Brazilian Society of Cardiology<sup>4</sup>. Other factors that support the reasoning for ischemic cardiopathy are the clinical history data, such as retrosternal pressure and dyspnea (ischemic equivalent), in addition to the electrocardiographic alterations, such as the electrically inactive region in the inferior wall and the poor R wave progression in the anterior wall.</p>
      <p>The bariatric surgery was indicated during the patient's evolution. The current recommendations for this procedure, which were published at the Latin-American Obesity Consensus<sup>5</sup> are: BMI <underline>&gt;</underline> 40 kg/m&#178; or BMI <underline>&gt;</underline> 35 kg/m&#178; associated with a comorbidity, such as sleep apnea, type II diabetes mellitus, systemic arterial hypertension, dyslipidemia, difficulty in locomotion, among others. The patient must have at least 5 years of obesity evolution and the conventional methods of weight management carried out by qualified professionals must have failed. Therefore, the present case presented a solid indication for the bariatric surgery.</p>
      <p>At 59 years, the patient had a syncope episode and needed to be hospitalized at another service. There is no report in the clinical history of the characteristics of the syncope, its investigation, or whether there was cranioencephalic trauma. Considering the medications given at the time of the hospital release, a diagnosis of a first episode of atrial fibrillation was attained during this hospitalization, as the patient was released anticoagulated on Warfarin and was also receiving digoxin for possible control of ventricular response. One week after the release he was brought back to the hospital with a neurological condition compatible with cerebrovascular accident. The ECG confirmed the finding of atrial fibrillation, in addition to a mean heart rate of 142 bpm, frequent ventricular extrasystoles, probable electrically inactive area in the inferior wall and decrease in septal strength and left potential.</p>
      <p>The skull tomography showed parieto-occipital hematoma and subarachnoid hemorrhage. The prothrombin time at the admission was increased, with an INR of 12.</p>
      <p>This patient, according to the Guidelines for the Management of Patients with Atrial Fibrillation of ACC/AHA<sup>6</sup>, presented persistent atrial fibrillation (duration <underline>&gt;</underline> 7 days) and high risk for thromboembolic phenomena. There are several scores that attempt to predict the risk of thromboembolic phenomena in patients with nonvalvular atrial fibrillation. Currently, one of the most often used is the CHADS2 score, which gives points to five risk factors for embolic events, as follows: heart failure, arterial hypertension, age <underline>&gt;</underline> 75 years, diabetes mellitus, cerebrovascular accident/ transient ischemic attack - the first four criteria receive one point each and the last criterion receives 2 points. It is accepted that patients with a score <underline>&gt;</underline> 2 must be anticoagulated.</p>
      <p>The CHADS2 score of the present patient is 3 points and therefore, there is formal indication for the use of vitamin K antagonist. Nonetheless, it has been well documented in medical literature that anticoagulation with Warfarin presents a 2 to 5-fold increase in the risk of intracranial hemorrhage<sup>7,8</sup>. Half of the patients with brain hemorrhage due to Warfarin use die within 30 to 90 days of the event<sup>9</sup>, which demonstrates the severity of this complication. High-risk factors for brain hemorrhage in anticoagulant users are: concomitant use of ASA, falls with head trauma, significant alcohol consumption, SAH, age <underline>&gt;</underline> 75 years, history of cerebrovascular disease, intensity of the anticoagulation, amyloid angiopathy, tobacco use and Mexican or Asian ethnicity<sup>10,11</sup>. However, according to some reports<sup>12,13</sup>, the risk of subdural hematoma caused by falls in anticoagulated patients is so small that patients who present a 3-point CHADS2 score (risk of CVA 5%/year without anticoagulation) would have to fall 300 times during one year for the risk of anticoagulation to be higher than its benefit.</p>
      <p>Our patient was receiving 100mg of ASA in association with Warfarin, was hypertensive, had a syncope one week before the cerebral hemorrhage and it was not clear whether there was brain trauma and presented an INR of 12 at the hospital admission. Therefore, he presented several risk factors for brain hemorrhage. Considering these aspects, which would be the mechanisms through by which the anticoagulants would increase the incidence of brain hemorrhage?</p>
      <p>It is currently known that aging often causes small arterioles in the brain to become fragile and undergo rupture. Most ruptures form autolimited and subclinical bleeding foci, called microbleeds, which can be demonstrated in autopsies or through the use of specific sequences of magnetic resonance<sup>14</sup>. This phenomenon is quite prevalent in hypertensive patients and in individuals older than 75 years. Occasionally, the blood leak caused by this arteriolar weakness and rupture cannot be contained by hemostatic mechanisms and by the adjacent tissues, resulting in more severe bleeding with clinical implications. This is the physiopathology of spontaneous intracranial hemorrhage.</p>
      <p>Anticoagulants increase the probability of these spontaneous ruptures becoming more severe bleeding episodes with clinical manifestations. In other words, anticoagulants disclose asymptomatic brain microbleeds, turning them into larger bleeds with obvious clinical signs. That is the reason why the high-risk factors for spontaneous intracranial hemorrhage are the same for bleeding due to the use of anticoagulants<sup>15</sup>.</p>
      <p>Another noteworthy fact regarding the patient's clinical history is the high levels of leptin in the blood. Leptin is a hormone secreted by the adipocytes, of which function is to produce the sensation of satiety, in addition to participating in the regulation of the body energy balance. In 1950, Ingalls and cols.<sup>16</sup> described a new species of mutant obese rats characterized by significant hyperphagia and decreased energy expenditure. Subsequently, it was described that the substance which was not produced by the ob/ob rats was leptin. It is currently known that the rise in serum leptin is common in obese humans and characterizes resistance to the leptin found in this population. This rise is associated with the syndrome of insulin resistance and thus, with cardiovascular diseases.</p>
      <p>In 1999, S&#246;derberg and cols<sup>17</sup> reported that plasma leptin is strongly associated with the increased risk of a first event of hemorrhagic cerebrovascular accident, regardless of other cardiovascular risk markers, with leptin being an important link in the development of cardiovascular diseases in obese individuals. Therefore, leptin resistance can be an interface of the metabolic deregulation with inflammation in the pathogenesis of obesity, its comorbidities and finally, of cardiovascular diseases.</p>
      <p>After the brain hemorrhage, the patient developed intracranial hypertension syndrome, a lowering of the level of consciousness and needed orotracheal intubation. After the draining of the intraparenchymatous hemorrhage, he developed pneumonia associated with the mechanical ventilation, characterized by the purulent secretion through the cannula, fever and leukocytosis. The incidence of pneumonia associated with the mechanical ventilation described in the literature is 3%/day in the first week of intubation, 2%/day in the second week and 1%/day in the third week<sup>18</sup>; therefore, it is a quite common complication. On May 20, 2006, the patient was in septic shock due to pneumonia by <italic>Burkholderia cepacia</italic>, which rapidly developed into multiple-organ failure and death on May 22, 2006.</p>
      <p>
        <bold>Dr. Pedro Veronese</bold>
      </p>
      <p>
        <bold>Diagnostic hypothesis</bold>
      </p>
      <p>Obesity grade III; primary and/or secondary SAH, due to possible apnea/hypopnea syndrome; type II diabetes mellitus; metabolic syndrome; subclinical hypothyroidism; hypertensive retinopathy; hypertensive dilated and/or ischemic cardiomyopathy; persistent chronic atrial fibrillation; Warfarin intoxication; brain hemorrhagic syndrome; intraparenchymatous hematoma and subarachnoid hemorrhage with intracranial hypertension syndrome; and septic shock due to in-hospital pneumonia due to <italic>B. cepacia</italic></p>
      <p>
        <bold>Dr. Pedro Veronese</bold>
      </p>
      <p>
        <bold>Necropsy</bold>
      </p>
      <p>Cadaver of patient with severe obesity, presenting a recent surgical incision of right temporoparietal craniotomy. The heart was large and weighed 866 g, with hypertrophy and dilatation of the four chambers, with multiple small foci of interstitial fibrosis in both ventricles (<xref ref-type="fig" rid="f2-body2">Figure 2</xref>). Vegetation was found in the atrial region of the posterior cusp of the mitral valve, measuring 1.5 cm in extension, and in the semilunar cusps of the pulmonary valve (the largest measuring 0.8 cm), with the presence of numerous colonies of Gram-positive cocci (<xref ref-type="fig" rid="en_23f03-body2">Figure 3</xref>). The heart valves did not show signs of rheumatic disease sequelae or evidence of any previous anatomopathological alterations. The epicardial coronary arteries presented slight atherosclerosis, as well as the aorta, with no obstructive lesions.</p>
      <p content-type="asset">
        <fig id="en_23f03-body2">
          <graphic xlink:href="1678-4170-abc-94-02-0282-00023-gf02-en.jpg"/></fig>
      </p>
      <fig id="f2-body2">
        <graphic xlink:href="1678-4170-abc-94-02-0282-00023-gf03-en.jpg"/></fig>
      <p>There were microabscesses and bacterial colonies in the myocardium, kidneys and spleen, with focal macroscopic infarctions in the latter two (<xref ref-type="fig" rid="f4-body2">Figure 4</xref>). The brain weighed 1,428 g and presented edema in the right hemisphere, in addition to extensive hemorrhagic infarction that affected the cortex and the white substance on this side and hemorrhage in the lateral ventricles (<xref ref-type="fig" rid="f5-body2">Figure 5</xref>).The histochemical screening for bacteria was negative in this organ. The lungs presented congestion, edema and areas of macrophage accumulation, containing hemosiderotic pigment in the alveolar spaces. The liver presented centrilobular sinusoidal dilatation, with areas of recent hemorrhagic necrosis. The kidneys presented foci of glomerular sclerosis and interstitial fibrosis. There were large greenish calculi in the gall bladder, which measured 1 to 2 cm each.</p>
      <fig id="f4-body2">
        <graphic xlink:href="1678-4170-abc-94-02-0282-00023-gf04-en.jpg"/></fig>
      <fig id="f5-body2">
        <graphic xlink:href="1678-4170-abc-94-02-0282-00023-gf05-en.jpg"/></fig>
      <p>
        <bold>Dr. Luiz Alberto Benvenuti</bold>
      </p>
      <p>
        <bold>Anatomopathological diagnoses</bold>
      </p>
      <p>Morbid obesity; systemic arterial hypertension; diabetes mellitus; cholelithiasis; hypertensive cardiopathy at dilated phase; infectious endocarditis of the mitral and pulmonary valves; hemorrhagic brain infarction; septicemia (cause of death).</p>
      <p>
        <bold>Dr. Luiz Alberto Benvenuti</bold>
      </p>
      <p>
        <bold>Comments</bold>
      </p>
      <p>The present case describes a 59-year-old male presenting morbid obesity as the main disease, accompanied by systemic arterial hypertension, diabetes mellitus and cholelithiasis, comorbidities which are frequently associated with this disease<sup>19</sup>. The hypertension was difficult to control and the patient developed decompensated hypertensive cardiopathy and progressive congestive heart failure. In spite of the existence of risk factors, he did not develop significant atherosclerosis in any arterial territory and did not present coronariopathy.</p>
      <p>The cause of death was bacterial septicemia secondary to infectious endocarditis of the mitral and pulmonary valves by Gram-positive cocci. The bacterium <italic>Burkholderia cepacia</italic>, identified at the blood culture shortly before the death, is a Gram-negative agent and thus, not likely to be responsible for the endocarditis. In addition to the simultaneous involvement of the pulmonary valve, another unusual aspect is that both affected valves (mitral and pulmonary) were previously normal, that is, did not present previous disease sequelae. The initial clinical manifestation of the endocarditis was neurological, due to the extensive hemorrhagic cerebral infarction, probably due to an embolic cause. The necropsy showed indisputable evidence of septic embolization, with the presence of microabscesses and bacterial colonies in the spleen, kidneys and myocardium. Although diabetes mellitus is generally considered a predisposing factor for infection, it has not been classically considered as a risk factor for the development of infectious endocarditis. However, this concept has been recently modified due to reports of the association between these two entities, as in the present case, as well as the more severe endocarditis in insulin-dependent diabetic patients<sup>20, 21</sup>.</p>
      <p>
        <bold>Dr. Luiz Alberto Benvenuti</bold>
      </p>
      <p>
        <bold>References</bold>
      </p>
    </body>
  </sub-article>
  <sub-article article-type="translation" id="TRes" xml:lang="es">
    <front-stub>
      <article-categories/>
      <title-group>
        <article-title xml:lang="es">Caso 1 - var&#243;n de 59 a&#241;os con obesidad acentuada, hipertensi&#243;n arterial, insuficiencia cardiaca y sometido a anticoagulaci&#243;n para fibrilaci&#243;n atrial, present&#243; accidente cerebrovascular y septicemia</article-title>
      </title-group>
    </front-stub>
    <body>
      <p>
        <bold>CORRELACI&#211;N ANATOMOCLINICA</bold>
      </p>
      <p>
        <fn id="top-body3">
          <label>
            <bold>Caso 1 - var&#243;n de 59 a&#241;os con obesidad acentuada, hipertensi&#243;n arterial, insuficiencia cardiaca y sometido a anticoagulaci&#243;n para fibrilaci&#243;n atrial, present&#243; accidente cerebrovascular y septicemia</bold>
          </label>
          <p>
            <bold>Pedro Veronese; Luiz Alberto Benvenuti</bold>
          </p>
        </fn>
      </p>
      <p>Instituto do Cora&#231;&#227;o (InCor) HC-FMUSP, S&#227;o Paulo, SP - Brasil</p>
      <p>Correspond&#234;ncia</p>
      <p><bold>Palabras clave: </bold> Obesidad, hipertensi&#243;n, insuficiencia cardiaca, accidente cerebrovascular, sepsis.</p>
      <p>Var&#243;n obeso de 59 a&#241;os de edad ingres&#243; en la internaci&#243;n con hemiplej&#237;a izquierda.</p>
      <p>Se atendi&#243; al paciente por primera vez en el Hospital a los 54 a&#241;os de edad, en raz&#243;n de crisis de disnea intensa e hipertensi&#243;n arterial.</p>
      <p>Recibi&#243; el diagn&#243;stico de hipertensi&#243;n arterial a los 44 a&#241;os de edad, cuando present&#243; cuadro de disnea intensa e hipertensi&#243;n arterial con niveles de tensi&#243;n de 220/120 mmHg. Requiri&#243; atenci&#243;n m&#233;dica de emergencia y lo medicaron. Evolucion&#243; con disnea, acompa&#241;ada de sudoraci&#243;n profusa y dolor opresivo retroesternal desencadenados por esfuerzos moderados. Llev&#243; a cabo tratamiento irregular. En la evoluci&#243;n, present&#243; episodios de ronco intenso durante el sue&#241;o con sensaci&#243;n de sofocaci&#243;n al despertar. El paciente sab&#237;a ser obeso desde la juventud, con todo hubo mayor ganancia de peso desde la edad de 48 a&#241;os.</p>
      <p>El examen f&#237;sico (12 marzo 2001) revel&#243; peso de 163,8kg, altura de 1,74 m, &#237;ndice de masa corp&#243;rea 54,1 kg/m<sup>2</sup>, pulso de 84 lpm, presi&#243;n arterial de 200/110 mmHg. La semiolog&#237;a pulmonar fue normal. El shock de punta del coraz&#243;n fue palpado en el 6&#186; espacio intercostal, hacia fuera de la l&#237;nea hemiclavicular izquierda, y la ausculta no revel&#243; ruidos accesorios. Hab&#237;a soplo sist&#243;lico ++/4+ en &#225;rea mitral y borde esternal izquierdo. El abdomen estaba voluminoso, en fald&#243;n abdominal, sin visceromegalias. Hab&#237;a edema discreto de miembros inferiores y los pulsos en estos miembros estaban disminuidos.</p>
      <p>La radiograf&#237;a de t&#243;rax (7 marzo 2001) revel&#243; cardiomegalia +++/4+ con aumento global del coraz&#243;n;</p>
      <p>El electrocardiograma (7 marzo 2001) revel&#243; ritmo sinusal, frecuencia cardiaca 77 lpm, intervalo PR 172 ms, duraci&#243;n de QRS 96 ms, intervalo QT 372 ms, el eje de QRS a -30&#186; hacia tras, hab&#237;a entalladura inicial con onda QS III y aVF, onda R no progresiva de V1 a V3 y p&#233;rdida de potenciales en derivaciones izquierdas (<xref ref-type="fig" rid="es_23f01-body3">Figura 1</xref>).</p>
      <p content-type="asset">
        <fig id="es_23f01-body3">
          <graphic xlink:href="1678-4170-abc-94-02-0282-00023-gf01-es.jpg"/></fig>
      </p>
      <p>Los ex&#225;menes laboratoriales (8 marzo 2001) revelaron 14,4 g/dl de hemoglobina, hematocrito el 43%, &#225;cido &#250;rico 9 mg/dl, creatinina 1,6 mg/dl, potasio 4,4 mEq/l, sodio 145 mEq/l, glucemia de ayuno 148 mg/dl, colesterol total 121 mg/dl, triglic&#233;ridos 57 mg/dl; el examen de orina revel&#243; proteinuria de 0,25 g/l, sin otras alteraciones. El nivel de TSH fue 5,28 U/ml, T4 libre 1,1 ng/dl, leptina 31 ng/ml (normal 3,8 &#177; 1,8 ng/ml), testosterona 336 ng/ml, FSH 2,6 UI/l, LH 2,0 UI/l, estradiol 40,2 pg/ml, insulina 7,9 Ul/ml, cortisol urinario 261 g/24 h y sulfato de dehidroepiandrostenediona 1.457 ng/ml.</p>
      <p>El ecocardiograma (26 abr 2001) revel&#243; espesor de septo y de pared posterior de 10 mm, di&#225;metro de aorta de 32 mm, de atrio izquierdo de 52 mm, di&#225;metro diast&#243;lico de ventr&#237;culo izquierdo de 70 mm y el sist&#243;lico 57 mm, con fracci&#243;n de eyecci&#243;n del 46%, por hipocinesia difusa acentuada. Hab&#237;a insuficiencia mitral moderada.</p>
      <p>El ultrasonido de ri&#241;ones revel&#243; ambos en tama&#241;o normal, los dos con 12,1 cm de longitud; mientras que el h&#237;gado presentaba esteatosis: y hab&#237;a se&#241;ales sugestivas de litiasis biliar.</p>
      <p>Se medic&#243; al paciente con 40 mg de enalapril, 40 mg de furosemida, 25 mg de clortalidona, 5 mg de amlodipina, 500 mg de metildopa, 25 mg de espironolactona, 100 mg de &#225;cido acetilsalic&#237;lico y 1.700 mg de metformina diarios, adem&#225;s de recomendaci&#243;n de dieta pobre en sal, hipocal&#243;rica y para diabetes. Con estas medidas el paciente perdi&#243; 28 kg de peso, hubo mejora de los s&#237;ntomas y la presi&#243;n arterial se reduzco para 150/90 mmHg.</p>
      <p>Despu&#233;s de tres a&#241;os, pesaba 149 kg, la presi&#243;n arterial era de 180/130 mmHg.</p>
      <p>El fondo de ojo revel&#243; retina con exudados en regi&#243;n temporal, cruzamientos arteriovenosos anormales con estasis venosa y estrechamiento del reflejo arterial, compatible con retinopat&#237;a hipertensiva</p>
      <p>Los ex&#225;menes laboratoriales (feb 2004) revelaron colesterol 172 mg/dl, HDL-colesterol 41 mg/dl, LDL-colesterol 114 mg/dl, triglic&#233;ridos 87 mg/dl, creatinina 1,1 mg/dl, urea 29 mg/dl y glucemia 126 mg/dl.</p>
      <p>Hubo aumento de la dosis diaria de metformina para 2.550 mg y de la furosemida para 80 mg/d&#237;a y se indic&#243; cirug&#237;a bari&#225;trica.</p>
      <p>Ha estado evolucionando poco sintom&#225;tico hasta que en abril del 2006 present&#243; s&#237;ncope y qued&#243; internado en hospital pr&#243;ximo a su residencia y recibi&#243; alta con prescripci&#243;n de 75 mg de captopril, 40 mg de furosemida, 0,25 mg de digoxina, 100 mg de &#225;cido acetilsalic&#237;lico y 5 mg de warfarina. Una semana despu&#233;s del alta present&#243; confusi&#243;n mental, disartria, desv&#237;o de rima oral hacia la derecha y hemiplej&#237;a izquierda. Le trajeron al Hospital para atenci&#243;n m&#233;dica de emergencia (16 mayo 2006).</p>
      <p>El examen f&#237;sico revel&#243; paciente so&#241;oliento, Glasgow 12/13, pupilas fotorreactivas y sin se&#241;ales de irritaci&#243;n men&#237;ngea, la frecuencia de pulso 100 lpm, la presi&#243;n arterial 130/80 mmHg y hemiplej&#237;a izquierda.</p>
      <p>El electrocardiograma revel&#243; fibrilaci&#243;n atrial, frecuencia cardiaca promedio de 142 lpm, con frecuentes extras&#237;stoles ventriculares, probable &#225;rea el&#233;ctricamente inactiva en pared inferior, disminuci&#243;n de fuerzas septales y de potenciales izquierdos.</p>
      <p>La tomograf&#237;a de cr&#225;neo revel&#243; hematoma parieto-occipital derecho y hemorragia subaracnoidea.</p>
      <p>El tiempo de protrombina (INR) fue de 12 y se administraron 5 unidades de plasma fresco fr&#237;o y vitamina K 10 mg. Debido a la alteraci&#243;n de la coagulaci&#243;n se indic&#243; tratamiento cl&#237;nico con prescripci&#243;n de dexametasona y fenitoina.</p>
      <p>Nueva tomograf&#237;a (18 mayo) no revel&#243; alteraci&#243;n significativa respecto al examen previo.</p>
      <p>En el tercer d&#237;a de la internaci&#243;n (19 mayo) hubo empeoramiento del nivel de conciencia y el paciente necesit&#243; intubaci&#243;n orotraqueal para soporte ventilatorio. Se tuvo en cuenta nuevamente la intervenci&#243;n neuroquir&#250;rgica.</p>
      <p>Los ex&#225;menes laboratoriales (19 mayo) revelaron hemoglobina 11,5 g/dl. Leucocitos 12.000/mm<sup>3</sup>, plaquetas 219000/3, creatinina 0,8 mg/dl, INR 1,94.</p>
      <p>Se llev&#243; a cabo drenaje de hemorragia intraparenquimatosa (20 mayo). El paciente evolucion&#243; con cuadro de fiebre y shock s&#233;ptico, atribuido a bronconeumonia, ya que hab&#237;a drenaje de secreci&#243;n purulenta por la sonda endotraqueal.</p>
      <p>Present&#243; hipertermia (38,5&#176;C) en 20, 21 y 22 mayo y se administraron 4 g de cefepime y 1 g vancomicina diarios a partir de 21 sep.</p>
      <p>Se aisl&#243; <italic>Burkholderia cepacia</italic> en la hemocultura (21 may 2006), sensible a la ceftazidima, meropenen y sulfametoxazol-trimetoprin. Los ex&#225;menes laboratoriales revelaron leucocitosis y empeoramiento progresivo de la funci&#243;n renal (<xref ref-type="table" rid="t1-body3">Tabla 1</xref>). Pese al uso de f&#225;rmaco vasoactivos y de antibi&#243;ticos, no hubo mejora del cuadro. El paciente present&#243; parada cardiorrespiratoria en asistolia no responsiva a las medidas de resucitaci&#243;n, y falleci&#243; (22 mayo 2006).</p>
      <table-wrap id="t1-body3">
        <graphic xlink:href="1678-4170-abc-94-02-0282-00023-gt01-es.jpg"/></table-wrap>
      <p>
        <bold>Aspectos cl&#237;nicos</bold>
      </p>
      <p>El caso relata la historia de un var&#243;n de 59 a&#241;os, obeso desde la juventud y que a los 44 a&#241;os de edad tuvo el diagn&#243;stico de hipertensi&#243;n arterial sist&#233;mica (HAS), cuando dio entrada en un servicio de emergencia con disnea intensa y presi&#243;n arterial de 220x120 mmHg. Debido a la mala adherencia a su tratamiento, empez&#243; a presentar disnea a los moderados esfuerzos, acompa&#241;ada de sudoraci&#243;n profusa y dolor opresiva retroesternal. A los 54 a&#241;os, cuando le atendieron por primera vez en el hospital, estaba con IMC 54,1 kg/m&#178;, FC 84 lpm, nuevamente hipertenso con presi&#243;n de 200x110 mmHg ya manifestaba se&#241;ales de lesiones en &#243;rganos blancos. Ten&#237;a el coraz&#243;n dilatado, revelado por un ictus desviado con relaci&#243;n a la l&#237;nea hemiclavicular y palpable en el 6&#186; espacio intercostal y soplo sist&#243;lico regurgitativo en el foco mitral (+2/4), compatible con insuficiencia mitral. El &#225;rea cardiaca era aumentada a la radiograf&#237;a de t&#243;rax (+3/4) y el ecocardiograma transtor&#225;cico mostraba dilataci&#243;n de ventr&#237;culo izquierdo con disfunci&#243;n moderada e hipocinesia difusa y dilataci&#243;n de atrio izquierdo adem&#225;s de insuficiencia mitral moderada, probablemente secundaria a la dilataci&#243;n cardiaca. Ten&#237;a lesi&#243;n renal evidenciada por proteinuria (0,25 g/l) y tres a&#241;os despu&#233;s ya presentaba retinopat&#237;a hipertensiva caracterizada por exudados en regi&#243;n temporal de la retina, cruces arteriovenosos anormales con estasis venosa y estrechamiento del reflejo arterial.</p>
      <p>Los factores que sugieren que la HAS del paciente arriba sea primaria son: el inicio tard&#237;o de la misma, a los 44 a&#241;os, y el hecho de que aproximadamente el 90% de las HAS sean primarias seg&#250;n registrado en la V Directriz Brasile&#241;a de Hipertensi&#243;n Arterial<sup>1</sup> y en el <italic>The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure</italic><sup>2</sup>. Sin embargo, en la historia cl&#237;nica del paciente hay algunos elementos que obligatoriamente llevan a pensar en causas secundarias de HAS, como: hipertensi&#243;n arterial estadio tres (caracterizada por presi&#243;n sist&#243;lica <underline>&gt;</underline> 180 mmHg y/o presi&#243;n diast&#243;lica <underline>&gt;</underline> 110 mmHg) y episodios de ronco intenso durante el sue&#241;o con sensaci&#243;n de sofocaci&#243;n al despertar, altamente sugestivo del s&#237;ndrome de la apnea/hipopnea del sue&#241;o, hoy sabidamente causa de HAS secundaria. No obstante, una investigaci&#243;n adicional debe hacerse para la confirmaci&#243;n de este diagn&#243;stico.</p>
      <p>El paciente, durante su historia cl&#237;nica, present&#243; cuadro de disnea progresiva hasta desencadenarse, a los moderados esfuerzos, edema de miembros inferiores y con ecocardiograma que revel&#243; disfunci&#243;n sist&#243;lica, todos estos, se&#241;ales de insuficiencia cardiaca, debido a la cardiopat&#237;a hipertensiva. Para corroborar este diagn&#243;stico, tenemos HAS estadio tres de dif&#237;cil control, lesiones causadas por la HAS en otros &#243;rganos blanco, como ri&#241;ones y retina, adem&#225;s de la ausencia de compromiso segmentar del ventr&#237;culo izquierdo. Sin embargo, la investigaci&#243;n de enfermedad arterial coronaria (EAC) en este paciente fue bastante pobre, y no fue posible descartar causa isqu&#233;mica de la cardiopat&#237;a dilatada. El racional para esta afirmaci&#243;n est&#225; en el hecho de los inn&#250;meros factores de riesgo que el paciente presentaba para EAC, entre ellos: HAS y diabetes melito tipo II, ya que segundo el Consenso de la Sociedad Brasile&#241;a de Diabetes<sup>3</sup>, present&#243; dos glucemias de ayuno <underline>&gt;</underline> 126 mg/dl (respectivamente 148 mg/dl y 126 mg/dl); pese a no ser dislipid&#233;mico, como en la presencia de diabetes, su LDL blanco deber&#237;a ser al menos <underline>&lt;</underline> 100 mg/dl, de acuerdo con lo recomendado por la IV Directriz Brasile&#241;a Sobre Dislipidemia y Prevenci&#243;n de la aterosclerosis de la Sociedad Brasile&#241;a de Cardiolog&#237;a<sup>4</sup>; obesidad grado III (&#237;ndice de masa corp&#243;rea <underline>&gt;</underline> 40 kg/m&#178;) y s&#237;ndrome metab&#243;lico caracterizado en este caso por: circunferencia abdominal <underline>&gt;</underline> 94 cm, presi&#243;n arterial <underline>&gt;</underline> 130x85 mmHg y glucemia de ayuno <underline>&gt;</underline> 100 mg/dl de acuerdo con los criterios de la Federaci&#243;n Internacional de Diabetes, publicados en la IV Directriz Brasile&#241;a Sobre Dislipidemia y Prevenci&#243;n de la Aterosclerosis de la Sociedad Brasile&#241;a de Cardiolog&#237;a<sup>4</sup>. Otros hechos conmemorativos que refuerzan el racional para cardiopat&#237;a isqu&#233;mica son dados de la historia cl&#237;nica tales como dolor opresivo retroesternal y disnea (equivalente isqu&#233;mico); adem&#225;s de las alteraciones electrocardiogr&#225;ficas, como la zona el&#233;ctricamente inactiva en pared inferior y la mala progresi&#243;n de R en la pared anterior.</p>
      <p>Durante la evoluci&#243;n del paciente se indic&#243; la realizaci&#243;n de cirug&#237;a bari&#225;trica. Las recomendaciones actuales para indicaci&#243;n de este procedimiento que se publicaron en el Consenso Latinoamericano de Obesidad<sup>5</sup> son: IMC <underline>&gt;</underline> 40 kg/m&#178; &#243; IMC <underline>&gt;</underline> 35 kg/m&#178; asociado a comorbilidad como apnea del sue&#241;o, diabetes melito tipo II, hipertensi&#243;n arterial sist&#233;mica, dislipidemia, dificultad de locomoci&#243;n entre otras. Los pacientes deben tener como m&#237;nimo 5 a&#241;os de evoluci&#243;n de la obesidad, con fracaso de los m&#233;todos convencionales para adelgazamiento realizados por profesionales calificados. Por tanto el paciente del caso en cuesti&#243;n ten&#237;a s&#243;lida indicaci&#243;n para someterse a la cirug&#237;a bari&#225;trica.</p>
      <p>A los 59 a&#241;os el paciente tuvo un episodio de s&#237;ncope necesitando internaci&#243;n hospitalaria en otro servicio. No hay relato en la historia de las caracter&#237;sticas del s&#237;ncope, ni sobre su investigaci&#243;n, tampoco hubo traumatismo craneoencef&#225;lico. Por las medicaciones del alta hospitalaria probablemente se hizo el diagn&#243;stico de un primer episodio de fibrilaci&#243;n atrial en esta internaci&#243;n, ya que el paciente se fue a casa anticoagulado con warfarina y digoxina para posible control de la respuesta ventricular. Tras una semana del alta, ingres&#243; nuevamente en el hospital con cuadro neurol&#243;gico compatible con accidente cerebrovascular. El electrocardiograma confirm&#243; el hallazgo de fibrilaci&#243;n atrial, adem&#225;s de la frecuencia cardiaca promedio de 142 lpm, frecuentes extras&#237;stoles ventriculares, probable &#225;rea el&#233;ctricamente inactiva en pared inferior, disminuci&#243;n de las fuerzas septales y de potenciales izquierdos. La tomograf&#237;a de cr&#225;neo revel&#243; hematoma parieto-occiptal y hemorragia subaracnoidea. El tiempo de protrombina en el ingreso estaba alargado con INR de 12.</p>
      <p>Este paciente, conforme las Directrices para Atenci&#243;n de Pacientes con Fibrilaci&#243;n Atrial de la ACC/AHA<sup>6</sup>, presentaba fibrilaci&#243;n atrial persistente (duraci&#243;n <underline>&gt;</underline> 7 d&#237;as) y un alto riesgo para fen&#243;menos tromboemb&#243;licos. Hay varios scores que intentan predecir el riesgo de fen&#243;menos tromboemb&#243;licos en pacientes con fibrilaci&#243;n atrial no valvular. Uno de los m&#225;s usados actualmente es el score CHADS2, que da puntos a cinco factores de riesgo para eventos emb&#243;licos, a saber: insuficiencia cardiaca, hipertensi&#243;n arterial, edad <underline>&gt;</underline> 75 a&#241;os, diabetes, accidente cerebrovascular/ataque isqu&#233;mico transitorio - los cuatro primeros criterios reciben 1 punto cada y el &#250;ltimo criterio 2 puntos. Se acepta que pacientes con scores <underline>&gt;</underline> 2 deban ser anticoagulados. El score CHADS2 del paciente en cuesti&#243;n es de 3 puntos y por tanto hay indicaci&#243;n formal del uso de antagonista de la vitamina K. Adem&#225;s de eso, tambi&#233;n es bien documentado en la literatura m&#233;dica que la anticoagulaci&#243;n con la warfarina aumenta el riesgo de hemorragia intracraneal en 2 a 5 veces<sup>7,8</sup>. Mitad de los pacientes con sangrado cerebral por la warfarina mueren dentro de los primeros 30 a 90 d&#237;as del evento<sup>9</sup>, lo que evidencia la severidad de esta complicaci&#243;n. Son factores de alto riesgo para sangrado cerebral en usuarios de anticoagulante oral: uso concomitante con AAS, ca&#237;da con trauma en la cabeza, consumo importante de alcohol, HAS, edad <underline>&gt;</underline> 75 a&#241;os, historia de enfermedad cerebrovascular, intensidad de la anticoagulaci&#243;n angiopat&#237;a amiloidea, uso de tabaco y etnia mexicana o asi&#225;tica<sup>10,11</sup>. No obstante, seg&#250;n algunos art&#237;culos<sup>12,13</sup>, el riesgo de hematoma subdural, resultante de ca&#237;da, en pacientes anticoagulados, es tan peque&#241;o que pacientes que totalicen 3 puntos en el score de CHADS2 (riesgo de ACV 5%/a&#241;o sin anticoagulaci&#243;n) necesitar&#237;an caer 300 veces en un a&#241;o para que el riesgo de la anticoagulaci&#243;n fuera mayor que su beneficio.</p>
      <p>Nuestro paciente recib&#237;a 100mg de AAS en asociaci&#243;n a la warfarina, era hipertenso, tuvo un s&#237;ncope una semana antes de la hemorragia cerebral, y no qued&#243; aclarado si hubo trauma craniano y si ten&#237;a un INR 12 en el ingreso hospitalario. Por tanto presentaba una serie de factores de riesgo para sangrado cerebral.</p>
      <p>Teniendo en cuenta estos aspectos, &#191;cu&#225;les ser&#237;an los mecanismos a trav&#233;s de los que los anticoagulantes aumentan la incidencia de sangrado cerebral? Actualmente se sabe que con el paso de la edad, peque&#241;as arter&#237;olas dentro del cerebro se fragilizan y se rompen con una cierta frecuencia. La mayor&#237;a de las rupturas forma focos de sangrados autolimitados y subcl&#237;nicos, llamados microsangrados, que se pueden demostrar en autopsias o por el uso de secuencias espec&#237;ficas de resonancia magn&#233;tica<sup>14</sup>. Este fen&#243;meno es mucho prevalente en hipertensos y en individuos arriba de lo 75 a&#241;os. Ocasionalmente, los mecanismos hemost&#225;ticos y los tejidos adyacentes pueden no contener vaciamiento de sangre consecuente de esta fragilidad y ruptura arteriolar, adem&#225;s de producir sangrado mayor con repercusiones cl&#237;nicas. Esta es la fisiopatolog&#237;a de la hemorragia intracraneana espont&#225;nea. Los anticoagulantes aumentan la probabilidad de que estas rupturas espont&#225;neas se transformen en sangrados mayores y con manifestaciones cl&#237;nicas. En otras palabras, los anticoagulantes desenmascaran los microsangrados cerebrales asintom&#225;ticos, y los transforman en sangrados mayores y con cl&#237;nica exuberante. Por esto, los factores de alto riesgo para sangrado cerebral espont&#225;neo son los mismos para sangrado por el uso de anticoagulantes<sup>15</sup>.</p>
      <p>Otro hecho que llama la atenci&#243;n en relaci&#243;n con la historia cl&#237;nica del paciente son los elevados niveles de leptina en la sangre. La leptina es una hormona secretada por los adipocitos, que tiene la funci&#243;n de producir la sensaci&#243;n de saciedad, adem&#225;s de participar en la regulaci&#243;n del balance energ&#233;tico corporal. El 1950, Ingalls et al<sup>16</sup> describieron una nueva especie de ratones obesos mutantes que se caracterizaban por importante hiperfagia y por la disminuci&#243;n en el gasto energ&#233;tico. Posteriormente se describi&#243; que la sustancia que los ratones no produc&#237;an ob/ob, era la leptina. Hoy se sabe que la elevaci&#243;n de la leptina s&#233;rica es com&#250;n en humanos obesos y caracteriza una resistencia a la leptina encontrada en esta poblaci&#243;n. Esta elevaci&#243;n se asocia con el s&#237;ndrome de la resistencia insul&#237;nica y por tanto con enfermedades cardiovasculares.</p>
      <p>En el 1999, S&#246;derberg et al<sup>17</sup>. describieron que la leptina plasm&#225;tica est&#225; fuertemente asociada al riesgo aumentado de un primer evento de accidente cerebrovascular hemorr&#225;gico, independientemente de otros marcadores de riesgo cardiovascular, con la leptina como un importante eslab&#243;n en el desarrollo de enfermedades cardiovasculares en obesos. Por tanto, la resistencia a la leptina puede ser una interfaz de la desregulaci&#243;n metab&#243;lica con la inflamaci&#243;n en la patog&#233;nesis de la obesidad, sus comorbilidades y por &#250;ltimo, de las enfermedades cardiovasculares.</p>
      <p>Tras el sangrado cerebral, el paciente, evolucion&#243; con s&#237;ndrome de hipertensi&#243;n intracraneana, rebajamiento del nivel de conciencia y necesidad de intubaci&#243;n orotraqueal. Tras el drenaje de la hemorragia intraparenquimatosa evolucion&#243; con neumon&#237;a asociada a la ventilaci&#243;n mec&#225;nica, caracterizada por secreci&#243;n purulenta por la c&#225;nula, fiebre y leucocitosis. La incidencia de neumon&#237;a asociada a la ventilaci&#243;n mec&#225;nica descrita por la literatura es del 3%/d&#237;a en la primera semana de intubaci&#243;n, 2%/d&#237;a en la segunda y 1%/d&#237;a en la tercera semana<sup>18</sup>, por tanto constituye complicaci&#243;n mucho frecuente. El d&#237;a 20 de mayo de 2006 el paciente se encontraba en shock s&#233;ptico, debido a neumon&#237;a por <italic>Burkholderia cepacia</italic>, evolucionando r&#225;pidamente hacia disfunci&#243;n de m&#250;ltiples &#243;rganos y muerte el d&#237;a 22 de mayo del 2006.</p>
      <p>
        <bold>Dr. Pedro Veronese</bold>
      </p>
      <p>
        <bold>Hip&#243;tesis diagn&#243;sticas</bold>
      </p>
      <p>Obesidad grado III; HAS primaria y/o secundaria el posible s&#237;ndrome de la apnea/hipopnea del sue&#241;o; diabetes mellitus tipo II; s&#237;ndrome metab&#243;lico; hipotiroidismo subcl&#237;nico; retinopat&#237;a hipertensiva; cardiopat&#237;a dilatada hipertensiva y/o isqu&#233;mica; fibrilaci&#243;n atrial cr&#243;nica persistente; intoxicaci&#243;n warfar&#237;nica; s&#237;ndrome hemorr&#225;gico cerebral: hematoma intraparenquimatoso y hemorragia subaracnoidea con s&#237;ndrome de hipertensi&#243;n intracraneana; y shock s&#233;ptico por neumon&#237;a hospitalaria debido a <italic>B. cepacia</italic></p>
      <p>
        <bold>Dr. Pedro Veronese</bold>
      </p>
      <p>
        <bold>Necropsia</bold>
      </p>
      <p>Cad&#225;ver de paciente presentando acentuada obesidad, donde se not&#243; incisi&#243;n quir&#250;rgica reciente de craniotom&#237;a temporoparietal derecha. El coraz&#243;n era voluminoso y pesaba 866 g. Presentaba hipertrofia y dilataci&#243;n de las cuatro c&#225;maras, con m&#250;ltiples peque&#241;os focos de fibrosis intersticial en ambos ventr&#237;culos (<xref ref-type="fig" rid="f2-body3">Figura 2</xref>). Hab&#237;a vegetaciones en la porci&#243;n atrial de la c&#250;spide posterior de la v&#225;lvula mitral, con 1,5 cm de extensi&#243;n, y en las semilunares de la v&#225;lvula pulmonar (la mayor con 0,8 cm), donde se nota al examen histol&#243;gico la presencia de numerosas colonias de cocos Gram positivos (<xref ref-type="fig" rid="es_23f03-body3">Figura 3</xref>). Las v&#225;lvulas cardiacas no presentaban secuela de enfermedad reum&#225;tica o evidencia de cualesquiera alteraciones anatomopatol&#243;gicas previas. Las coronarias epic&#225;rdicas presentaban aterosclerosis discreta, as&#237; como la aorta, no habiendo lesiones obstructivas. Hab&#237;a microabscesos y colonias bacterianas en el miocardio, los ri&#241;ones y el bazo, con infartos macrosc&#243;picos focales en esos dos &#250;ltimos &#243;rganos (<xref ref-type="fig" rid="f4-body3">Figura 4</xref>). El enc&#233;falo pesaba 1.428 g, y hab&#237;a edema del hemisferio cerebral derecho, adem&#225;s de extenso infarto hemorr&#225;gico que afectaba el c&#243;rtex y la sustancia blanca de este lado y hemorragia en los ventr&#237;culos laterales (<xref ref-type="fig" rid="f5-body3">Figura 5</xref>). La investigaci&#243;n histoqu&#237;mica de bacterias fue negativa en este &#243;rgano. Los pulmones presentaban congesti&#243;n, edema y &#225;reas de acumulaci&#243;n de macr&#243;fagos que conten&#237;a pigmento hemosider&#243;tico en los espacios alveolares. El h&#237;gado presentaba dilataci&#243;n sinusoidal centrolobular, con &#225;reas de necrosis hemorr&#225;gica reciente. Los ri&#241;ones presentaban focos de esclerosis glomerular y fibrosis intersticial. Hab&#237;a grandes c&#225;lculos verdoso en la ves&#237;cula biliar, que mide de 1 a 2 cm cada.</p>
      <p content-type="asset">
        <fig id="es_23f03-body3">
          <graphic xlink:href="1678-4170-abc-94-02-0282-00023-gf02-es.jpg"/></fig>
      </p>
      <p>
        <bold>Dr. Luiz Alberto Benvenuti</bold>
      </p>
      <fig id="f2-body3">
        <graphic xlink:href="1678-4170-abc-94-02-0282-00023-gf03-es.jpg"/></fig>
      <fig id="f4-body3">
        <graphic xlink:href="1678-4170-abc-94-02-0282-00023-gf04-es.jpg"/></fig>
      <fig id="f5-body3">
        <graphic xlink:href="1678-4170-abc-94-02-0282-00023-gf05-es.jpg"/></fig>
      <p>
        <bold>Diagn&#243;sticos anatomopatol&#243;gicos</bold>
      </p>
      <p>Obesidad m&#243;rbida; hipertensi&#243;n arterial sist&#233;mica; diabetes mellitus; calculosis de la ves&#237;cula biliar; cardiopat&#237;a hipertensiva en fase dilatada; endocarditis infecciosa de las v&#225;lvulas mitral y pulmonar; infarto cerebral hemorr&#225;gico; septicemia (causa del &#243;bito).</p>
      <p>
        <bold>Dr. Luiz Alberto Benvenuti</bold>
      </p>
      <p>
        <bold>Comentarios</bold>
      </p>
      <p>Caso de var&#243;n de 59 a&#241;os de edad, que presenta como enfermedad principal la obesidad m&#243;rbida, acompa&#241;ada de hipertensi&#243;n arterial sist&#233;mica, diabetes mellitus y calculosis de la ves&#237;cula biliar, comorbilidades frecuentemente a ella asociadas<sup>19</sup>. La hipertensi&#243;n era de dif&#237;cil control y el paciente evolucion&#243; con cardiopat&#237;a hipertensiva descompensada e insuficiencia cardiaca congestiva progresiva. Pese a la existencia de factores de riesgo, no desarroll&#243; aterosclerosis significativa en ning&#250;n territorio arterial, y no hab&#237;a coronariopat&#237;a. La causa del &#243;bito fue septicemia bacteriana secundaria a la endocarditis infecciosa de las v&#225;lvulas mitral y pulmonar, por cocos Gram positivos. La bacteria <italic>Burkholderia cepacia,</italic> identificada en la hemocultura poco antes del &#243;bito es agente Gram negativo, y por tanto no imputamos a la misma a la etiolog&#237;a de la endocarditis. Adem&#225;s del compromiso simult&#225;neo de la v&#225;lvula pulmonar, otro aspecto no habitual es que ambas las v&#225;lvulas afectadas (mitral y pulmonar) eran previamente normales, es decir, no presentaban secuela de enfermedad anterior. La manifestaci&#243;n cl&#237;nica inicial de la endocarditis fue neurol&#243;gica, debido al extenso infarto cerebral hemorr&#225;gico de probable naturaleza emb&#243;lica. En la necropsia encontramos indiscutibles evidencias de embolizaci&#243;n s&#233;ptica, con la presencia de microabscesos y colonias bacterianas en el bazo, ri&#241;ones y miocardio. Pese a que la diabetes mellitus sea gen&#233;ricamente considerado como factor predisponente para infecci&#243;n, el mismo no viene siendo cl&#225;sicamente considerado como factor de riesgo para el desarrollo de endocarditis infecciosa. Sin embargo, este concepto se ha estado cambiando m&#225;s recientemente, debido a relatos de asociaci&#243;n entre estas dos entidades, como en el presente caso, y de la mayor severidad de la endocarditis en pacientes diab&#233;ticos dependientes de insulina<sup>20,21</sup>.</p>
      <disp-quote>
        <p>
          <bold>Dr. Luiz Alberto Benvenuti</bold>
        </p>
      </disp-quote>
      <p>
        <bold>Referencias</bold>
      </p>
    </body>
  </sub-article>
</article>
